ENUM Pengajuan SEC - Enumeral Biomedical Holdings, Inc.- Laporan Tahunan, Pernyataan Kuasa, Prospektus

Mga Batayang Estadistika

CIK

1561551

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Enumeral Biomedical Holdings, Inc.

SEC Filings (Chronological Order)

Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.

February 13, 2018	SC 13G/A	ENUM / Enumeral Biomedical Holdings, Inc. / PEIERLS E JEFFREY - ENUMERAL BIOMEDICAL HOLDINGS, INC. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Enumeral Biomedical Holdings, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 294017108 (CUSIP Number) December 31, 2017 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which this Sc
January 29, 2018	424B3	Prospectus Supplement No. 16 (To Prospectus filed on April 28, 2017, as supplemented by Prospectus Supplement No. 1 dated May 22, 2017, Prospectus Supplement No. 2 dated May 22, 2017, Prospectus Supplement No. 3 dated June 2, 2017, Prospectus Supplem Filed Pursuant to Rule 424(b)(3) and Rule 424(c) Registration No. 333-216533 Prospectus Supplement No. 16 (To Prospectus filed on April 28, 2017, as supplemented by Prospectus Supplement No. 1 dated May 22, 2017, Prospectus Supplement No. 2 dated May 22, 2017, Prospectus Supplement No. 3 dated June 2, 2017, Prospectus Supplement No. 4 dated June 14, 2017, Prospectus Supplement No. 5 dated June 26,
January 29, 2018	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement, Bankruptcy or Receivership UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 26, 2018 Enumeral Biomedical Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 000-55415 99-0376434 (State or Other Jurisdiction (Commission File
January 29, 2018	EX-2.1	Asset Purchase Agreement, dated as of January 26, 2018, by and between Enumeral Biomedical Holdings, Inc. and XOMA US LLC. Exhibit 2.1 FOR EXECUTION ASSET PURCHASE AGREEMENT THIS ASSET PURCHASE AGREEMENT is made as of the 26th day of January, 2018 (the ?Agreement?), by and between Enumeral Biomedical Holdings, Inc., a Delaware corporation with an address at 1337 Massachusetts Avenue #243, Arlington, MA. 02476 (?Seller?), and XOMA US LLC, a Delaware limited liability company with its principal place of business at 2200
January 12, 2018	EX-99.A	AGREEMENT FOR JOINT FILING OF SCHEDULE 13G Exhibit A Exhibit A AGREEMENT FOR JOINT FILING OF SCHEDULE 13G Thomas A. Satterfield, Jr. and A.G. Family L.P. hereby agree to file jointly the statement on Schedule 13G to which this Agreement for Joint Filing of Schedule 13G (this “Agreement”) is attached, as well as any amendments thereto which may be deemed necessary, pursuant to Rule 13d-1(k) under the Securities Exchange Act of 1934. Each of
January 12, 2018	SC 13G/A	ENUM / Enumeral Biomedical Holdings, Inc. / SATTERFIELD THOMAS A JR - SC 13G/A Passive Investment SC 13G/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (Amendment No. 1)* Enumeral Biomedical Holdings, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 294017108 (CUSIP Number) December 31, 2017 (Date o
December 19, 2017	424B3	Prospectus Supplement No. 15 (To Prospectus filed on April 28, 2017, as supplemented by Prospectus Supplement No. 1 dated May 22, 2017, Prospectus Supplement No. 2 dated May 22, 2017, Prospectus Supplement No. 3 dated June 2, 2017, Prospectus Supplem Filed Pursuant to Rule 424(b)(3) and Rule 424(c) Registration No. 333-216533 Prospectus Supplement No. 15 (To Prospectus filed on April 28, 2017, as supplemented by Prospectus Supplement No. 1 dated May 22, 2017, Prospectus Supplement No. 2 dated May 22, 2017, Prospectus Supplement No. 3 dated June 2, 2017, Prospectus Supplement No. 4 dated June 14, 2017, Prospectus Supplement No. 5 dated June 26,
December 19, 2017	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 18, 2017 Enumeral Biomedical Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 000-55415 99-0376434 (State or Other Jurisdiction (Commission File
November 14, 2017	424B3	Prospectus Supplement No. 14 (To Prospectus filed on April 28, 2017, as supplemented by Prospectus Supplement No. 1 dated May 22, 2017, Prospectus Supplement No. 2 dated May 22, 2017, Prospectus Supplement No. 3 dated June 2, 2017, Prospectus Supplem Filed Pursuant to Rule 424(b)(3) and Rule 424(c) Registration No. 333-216533 Prospectus Supplement No. 14 (To Prospectus filed on April 28, 2017, as supplemented by Prospectus Supplement No. 1 dated May 22, 2017, Prospectus Supplement No. 2 dated May 22, 2017, Prospectus Supplement No. 3 dated June 2, 2017, Prospectus Supplement No. 4 dated June 14, 2017, Prospectus Supplement No. 5 dated June 26,
November 14, 2017	10-Q	ENUM / Enumeral Biomedical Holdings, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2017. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 000-55415 EN
October 31, 2017	424B3	Prospectus Supplement No. 13 (To Prospectus filed on April 28, 2017, as supplemented by Prospectus Supplement No. 1 dated May 22, 2017, Prospectus Supplement No. 2 dated May 22, 2017, Prospectus Supplement No. 3 dated June 2, 2017, Prospectus Supplem Filed Pursuant to Rule 424(b)(3) and Rule 424(c) Registration No. 333-216533 Prospectus Supplement No. 13 (To Prospectus filed on April 28, 2017, as supplemented by Prospectus Supplement No. 1 dated May 22, 2017, Prospectus Supplement No. 2 dated May 22, 2017, Prospectus Supplement No. 3 dated June 2, 2017, Prospectus Supplement No. 4 dated June 14, 2017, Prospectus Supplement No. 5 dated June 26,
October 31, 2017	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 27, 2017 Enumeral Biomedical Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 000-55415 99-0376434 (State or Other Jurisdiction of Incorporation)
October 27, 2017	424B3	Prospectus Supplement No. 12 (To Prospectus filed on April 28, 2017, as supplemented by Prospectus Supplement No. 1 dated May 22, 2017, Prospectus Supplement No. 2 dated May 22, 2017, Prospectus Supplement No. 3 dated June 2, 2017, Prospectus Supplem 424B3 1 s107892424b3.htm 424B3 Filed Pursuant to Rule 424(b)(3) and Rule 424(c) Registration No. 333-216533 Prospectus Supplement No. 12 (To Prospectus filed on April 28, 2017, as supplemented by Prospectus Supplement No. 1 dated May 22, 2017, Prospectus Supplement No. 2 dated May 22, 2017, Prospectus Supplement No. 3 dated June 2, 2017, Prospectus Supplement No. 4 dated June 14, 2017, Prospectus
October 27, 2017	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K 1 s1078818k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 23, 2017 Enumeral Biomedical Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware (State or Other Jurisdiction of Incorporati
October 27, 2017	EX-10.1	Form of Amendment No. 1 to Intellectual Property Security Agreement, dated as of October 23, 2017, by and among Enumeral Biomedical Holdings, Inc., Enumeral Biomedical Corp., and certain Subscribers who constitute Majority Holders. Exhibit 10.1 AMENDMENT NO. 1 To INTELLECTUAL PROPERTY SECURITY Agreement This Amendment No. 1 to Intellectual Property Security Agreement (this ?Amendment?) is made and entered into effective as of October 23, 2017, by and among Enumeral Biomedical Holdings, Inc., a Delaware corporation (the ?Company?), Enumeral Biomedical Corp., a Delaware corporation and wholly-owned subsidiary of the Company (t
September 22, 2017	424B3	Prospectus Supplement No. 11 (To Prospectus filed on April 28, 2017, as supplemented by Prospectus Supplement No. 1 dated May 22, 2017, Prospectus Supplement No. 2 dated May 22, 2017, Prospectus Supplement No. 3 dated June 2, 2017, Prospectus Supplem Filed Pursuant to Rule 424(b)(3) and Rule 424(c) Registration No. 333-216533 Prospectus Supplement No. 11 (To Prospectus filed on April 28, 2017, as supplemented by Prospectus Supplement No. 1 dated May 22, 2017, Prospectus Supplement No. 2 dated May 22, 2017, Prospectus Supplement No. 3 dated June 2, 2017, Prospectus Supplement No. 4 dated June 14, 2017, Prospectus Supplement No. 5 dated June 26,
September 22, 2017	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 19, 2017 Enumeral Biomedical Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 000-55415 99-0376434 (State or Other Jurisdiction (Commission Fil
September 5, 2017	424B3	Prospectus Supplement No. 10 (To Prospectus filed on April 28, 2017, as supplemented by Prospectus Supplement No. 1 dated May 22, 2017, Prospectus Supplement No. 2 dated May 22, 2017, Prospectus Supplement No. 3 dated June 2, 2017, Prospectus Supplem Filed Pursuant to Rule 424(b)(3) and Rule 424(c) Registration No. 333-216533 Prospectus Supplement No. 10 (To Prospectus filed on April 28, 2017, as supplemented by Prospectus Supplement No. 1 dated May 22, 2017, Prospectus Supplement No. 2 dated May 22, 2017, Prospectus Supplement No. 3 dated June 2, 2017, Prospectus Supplement No. 4 dated June 14, 2017, Prospectus Supplement No. 5 dated June 26,
September 5, 2017	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 1, 2017 Enumeral Biomedical Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 000-55415 99-0376434 (State or Other Jurisdiction (Commission File
August 25, 2017	424B3	Prospectus Supplement No. 9 (To Prospectus filed on April 28, 2017, as supplemented by Prospectus Supplement No. 1 dated May 22, 2017, Prospectus Supplement No. 2 dated May 22, 2017, Prospectus Supplement No. 3 dated June 2, 2017, Prospectus Suppleme Filed Pursuant to Rule 424(b)(3) and Rule 424(c) Registration No. 333-216533 Prospectus Supplement No. 9 (To Prospectus filed on April 28, 2017, as supplemented by Prospectus Supplement No. 1 dated May 22, 2017, Prospectus Supplement No. 2 dated May 22, 2017, Prospectus Supplement No. 3 dated June 2, 2017, Prospectus Supplement No. 4 dated June 14, 2017, Prospectus Supplement No. 5 dated June 26,
August 25, 2017	8-K	Termination of a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 23, 2017 Enumeral Biomedical Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 000-55415 99-0376434 (State or Other Jurisdiction of Incorporation)
August 15, 2017	EX-99.1	Joint Filing Agreement EX-99.1 2 enumeral13da-8x15x17xjfa.htm EXHIBIT 99.1 Exhibit 1 Joint Filing Agreement The undersigned hereby agree that a single Schedule 13D (or any amendment thereto) relating to the Common Stock and Warrants for Common Stock of Enumeral Biomedical Holdings, Inc. shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to such Schedule 13D. Dated: A
August 15, 2017	SC 13D/A	ENUM / Enumeral Biomedical Holdings, Inc. / HARRIS & HARRIS GROUP INC /NY/ - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 2 SCHEDULE 13D Under the Securities Exchange Act of 1934 Enumeral Biomedical Holdings, Inc. (Name of Issuer) Common Stock, par value $.001 per share (Title of Class of Securities) 294017108 (CUSIP Number) 180 Degree Capital Corp. 7 N. Willow Street, Suite 4B Montclair, New Jersey 07042 Attention: Daniel B. Wolfe
August 14, 2017	EX-99.1	Enumeral Reports Second Quarter Financial Results Exhibit 99.1 Enumeral Reports Second Quarter Financial Results CAMBRIDGE, Mass.?August 14, 2017-Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM) (?Enumeral? or the ?Company?) today announced its financial results for the three months ended June 30, 2017. On June 29, 2017, the Company?s Board of Directors, having evaluated and pursued a range of potential strategic transactions, and other alternati
August 14, 2017	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2017 Enumeral Biomedical Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 000-55415 99-0376434 (State or Other Jurisdiction (Commission File (
August 14, 2017	424B3	Prospectus Supplement No. 8 (To Prospectus filed on April 28, 2017, as supplemented by Prospectus Supplement No. 1 dated May 22, 2017, Prospectus Supplement No. 2 dated May 22, 2017, Prospectus Supplement No. 3 dated June 2, 2017, Prospectus Suppleme 424B3 1 s107182424b3.htm 424B3 Filed Pursuant to Rule 424(b)(3) and Rule 424(c) Registration No. 333-216533 Prospectus Supplement No. 8 (To Prospectus filed on April 28, 2017, as supplemented by Prospectus Supplement No. 1 dated May 22, 2017, Prospectus Supplement No. 2 dated May 22, 2017, Prospectus Supplement No. 3 dated June 2, 2017, Prospectus Supplement No. 4 dated June 14, 2017, Prospectus S
August 14, 2017	EX-10.2	Form of Subscription Agreement entered into between Enumeral Biomedical Holdings, Inc. and Investors in the May 19, 2017 Unit Offering. Exhibit 10.2 SUBSCRIPTION AGREEMENT Enumeral Biomedical Holdings, Inc. 200 CambridgePark Drive, Suite 2000 Cambridge, MA 02140 This Subscription Agreement (this “Agreement”) has been executed by the subscriber set forth on the signature page hereof (the “Subscriber”) in connection with the private placement offering (the “Offering”) of a minimum of $500,000 (the “Minimum Offering”) and a maximum o
August 14, 2017	EX-10.1	Placement Agency Agreement, dated as of May 12, 2017, by and between Enumeral Biomedical Holdings, Inc., Katalyst Securities LLC and GP Nurmenkari Inc., as amended. Exhibit 10.1 KATALYST SECURITIES LLC 630 THIRD AVENUE, 5TH FLOOR NEW YORK, NY 10017 TEL: 212-400-6993 FAX: 212-247-1059 Member: FINRA & SIPC GP NURMENKARI INC. 64 WALL STREET, SUITE 402 NORWALK, CT. 06850 TEL: 212-447-5550 Member: FINRA & SIPC PLACEMENT AGENCY AGREEMENT May 12, 2017 Mr. Wael Fayad Chairman, President and Chief Executive Officer Enumeral Biomedical Holdings, Inc. 200 CambridgePark
August 14, 2017	EX-10.6	Form of Investor Warrant issued by Enumeral Biomedical Holdings, Inc. in May 19, 2017 Unit Offering. Exhibit 10.6 Warrant Certificate No. NEITHER THE SECURITIES REPRESENTED HEREBY NOR THE SECURITIES ISSUABLE UPON THE EXERCISE OF THIS WARRANT HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY STATE SECURITIES LAWS, AND NEITHER SUCH SECURITIES NOR ANY INTEREST THEREIN MAY BE OFFERED, SOLD, PLEDGED, OR OTHERWISE TRANSFERRED UNLESS (1) A REGISTRATION STAT
August 14, 2017	EX-10.3	Escrow Agreement, dated as of May 9, 2017, by and among Enumeral Biomedical Holdings, Inc., Katalyst Securities LLC, GP Nurmenkari Inc., and Delaware Trust Company. Exhibit 10.3 ESCROW AGREEMENT Escrow Agreement (the “Escrow Agreement”) dated as of the effective date (the “Effective Date”) set forth on Schedule 1 hereto (“Schedule 1”) by and among the corporation identified as the “Company” on Schedule 1 hereto (the “Company”), the company identified on Schedule 1 hereto as Katalyst Securities LLC, (“Depositor #1”), the company identified on Schedule 1 hereto
August 14, 2017	EX-10.5	Intellectual Property Security Agreement, dated as of May 19, 2017, by and among Enumeral Biomedical Holdings, Inc., Enumeral Biomedical Corp., the Buyers named therein, and Intuitive Venture Partners, LLC, in its capacity as the Collateral Agent. EX-10.5 7 s107066ex10-5.htm EXHIBIT 10.5 Exhibit 10.5 INTELLECTUAL PROPERTY SECURITY AGREEMENT This Intellectual Property Security Agreement (this “Security Agreement”) is made as of May 19, 2017 by and among Enumeral Biomedical Holdings Inc. (the “Company”) and its subsidiary, Enumeral Biomedical Corp. (the “Subsidiary”), each a Delaware corporation, and each with offices at 200 CambridgePark Dri
August 14, 2017	EX-4.1	Form of 12% Senior Convertible Secured Promissory Note issued by Enumeral Biomedical Holdings, Inc. in May 19, 2017 Unit Offering. Exhibit 4.1 THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”). THESE SECURITIES MAY BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED ONLY (A) TO THE COMPANY, (B) OUTSIDE THE UNITED STATES IN COMPLIANCE WITH RULE 904 OF REGULATION S UNDER THE SECURITIES ACT, (C) IN COMPLIANCE WITH RULE 144 OR 144A THEREUNDE
August 14, 2017	10-Q	ENUM / Enumeral Biomedical Holdings, Inc. 10-Q (Quarterly Report) 10-Q 1 s10706610q.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2017. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission Fil
August 14, 2017	EX-10.4	Form of Registration Rights Agreement, dated as of May 19, 2017, by and among Enumeral Biomedical Holdings, Inc., Investors in the May 19, 2017 Unit Offering, Katalyst Securities LLC, and GP Nurmenkari Inc. Exhibit 10.4 Registration Rights Agreement This Registration Rights Agreement (this “Agreement”) is made and entered into effective as of May 19, 2017, among Enumeral Biomedical Holdings, Inc., a Delaware corporation (the “Company”), each of the persons who have executed omnibus or counterpart signature page(s) hereto (each, a “Subscriber” and, collectively, the “Subscribers”), and the persons or
August 14, 2017	EX-10.7	Form of Placement Agent Warrant issued by Enumeral Biomedical Holdings, Inc. in connection with May 19, 2017 Unit Offering Exhibit 10.7 Warrant Certificate No. NEITHER THE SECURITIES REPRESENTED HEREBY NOR THE SECURITIES ISSUABLE UPON THE EXERCISE OF THIS WARRANT HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY STATE SECURITIES LAWS, AND NEITHER SUCH SECURITIES NOR ANY INTEREST THEREIN MAY BE OFFERED, SOLD, PLEDGED, OR OTHERWISE TRANSFERRED UNLESS (1) A REGISTRATION STAT
August 14, 2017	EX-10.8	Amendment No. 2 to Study Agreement, dated as of May 31, 2017, between Enumeral Biomedical Holdings, Inc. and Merck Sharp & Dohme Corp. EX-10.8 10 s107066ex10-8.htm EXHIBIT 10.8 Exhibit 10.8 Execution Copy Confidential portions of this document have been redacted and omitted pursuant to a Request for Confidential Treatment filed with the Securities and Exchange Commission (the “SEC”) pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. The redacted and omitted portions are indicated with the notation “*” a
August 3, 2017	424B3	Prospectus Supplement No. 7 (To Prospectus filed on April 28, 2017, as supplemented by Prospectus Supplement No. 1 dated May 22, 2017, Prospectus Supplement No. 2 dated May 22, 2017, Prospectus Supplement No. 3 dated June 2, 2017, Prospectus Suppleme Filed Pursuant to Rule 424(b)(3) and Rule 424(c) Registration No. 333-216533 Prospectus Supplement No. 7 (To Prospectus filed on April 28, 2017, as supplemented by Prospectus Supplement No. 1 dated May 22, 2017, Prospectus Supplement No. 2 dated May 22, 2017, Prospectus Supplement No. 3 dated June 2, 2017, Prospectus Supplement No. 4 dated June 14, 2017, Prospectus Supplement No. 5 dated June 26,
August 3, 2017	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8-K 1 s1070198k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2017 Enumeral Biomedical Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 000-55415 99-0376434 (State or Other Jurisdict
August 1, 2017	EX-99.1	Joint Filing Agreement Exhibit 1 Joint Filing Agreement The undersigned hereby agree that a single Schedule 13D (or any amendment thereto) relating to the Common Stock and Warrants for Common Stock of Enumeral Biomedical Holdings, Inc.
August 1, 2017	SC 13D/A	ENUM / Enumeral Biomedical Holdings, Inc. / HARRIS & HARRIS GROUP INC /NY/ - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 SCHEDULE 13D Under the Securities Exchange Act of 1934 Enumeral Biomedical Holdings, Inc. (Name of Issuer) Common Stock, par value $.001 per share (Title of Class of Securities) 294017108 (CUSIP Number) 180 Degree Capital Corp. 7 N. Willow Street, Suite 4B Montclair, New Jersey 07042 Attention: Daniel B. Wolfe
June 30, 2017	424B3	Prospectus Supplement No. 6 (To Prospectus filed on April 28, 2017, as supplemented by Prospectus Supplement No. 1 dated May 22, 2017, Prospectus Supplement No. 2 dated May 22, 2017, Prospectus Supplement No. 3 dated June 2, 2017, Prospectus Suppleme Filed Pursuant to Rule 424(b)(3) and Rule 424(c) Registration No. 333-216533 Prospectus Supplement No. 6 (To Prospectus filed on April 28, 2017, as supplemented by Prospectus Supplement No. 1 dated May 22, 2017, Prospectus Supplement No. 2 dated May 22, 2017, Prospectus Supplement No. 3 dated June 2, 2017, Prospectus Supplement No. 4 dated June 14, 2017, and Prospectus Supplement No. 5 dated June
June 30, 2017	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Other Events 8-K 1 s1067278k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2017 Enumeral Biomedical Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 000-55415 99-0376434 (State or Other Jurisdict
June 26, 2017	424B3	Prospectus Supplement No. 5 (To Prospectus filed on April 28, 2017, as supplemented by Prospectus Supplement No. 1 dated May 22, 2017, Prospectus Supplement No. 2 dated May 22, 2017, Prospectus Supplement No. 3 dated June 2, 2017, and Prospectus Supp 424B3 1 s106688424b3.htm 424B3 Filed Pursuant to Rule 424(b)(3) and Rule 424(c) Registration No. 333-216533 Prospectus Supplement No. 5 (To Prospectus filed on April 28, 2017, as supplemented by Prospectus Supplement No. 1 dated May 22, 2017, Prospectus Supplement No. 2 dated May 22, 2017, Prospectus Supplement No. 3 dated June 2, 2017, and Prospectus Supplement No. 4 dated June 14, 2017) ENUMERAL
June 26, 2017	8-K	Costs Associated with Exit or Disposal Activities, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2017 Enumeral Biomedical Holdings, Inc. (Exact name of registrant as specified in its charter) (Exact name of registrant as specified in its charter) Delaware (State or Other
June 14, 2017	424B3	Prospectus Supplement No. 4 (To Prospectus filed on April 28, 2017, as supplemented by Prospectus Supplement No. 1 dated May 22, 2017, Prospectus Supplement No. 2 dated May 22, 2017, and Prospectus Supplement No. 3 dated June 2, 2017) ENUMERAL BIOMED 424B3 1 s106547424b3.htm 424B3 Filed Pursuant to Rule 424(b)(3) and Rule 424(c) Registration No. 333-216533 Prospectus Supplement No. 4 (To Prospectus filed on April 28, 2017, as supplemented by Prospectus Supplement No. 1 dated May 22, 2017, Prospectus Supplement No. 2 dated May 22, 2017, and Prospectus Supplement No. 3 dated June 2, 2017) ENUMERAL BIOMEDICAL HOLDINGS, INC. This Prospectus Supple
June 14, 2017	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2017 Enumeral Biomedical Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware (State or Other Jurisdiction of Incorporation) 000-55415 (Commission Fi
June 14, 2017	EX-10.1	Amendment No. 1 to Letter Agreement, dated as of June 9, 2017, between Arthur H. Tinkelenberg, Ph.D. and Enumeral Biomedical Holdings, Inc. Exhibit 10.1 AMENDMENT NO. 1 TO LETTER AGREEMENT This Amendment No. 1 to Letter Agreement (the ?Amendment?), dated as of June 9, 2017, amends that certain letter agreement (the ?Letter Agreement?), dated as of August 4, 2016, by and between Enumeral Biomedical Holdings, Inc. (with its subsidiaries, the ?Company?) and Arthur H. Tinkelenberg, Ph.D. (?Executive?). Capitalized word used but not otherw
June 2, 2017	424B3	Prospectus Supplement No. 3 (To Prospectus filed on April 28, 2017, as supplemented by Prospectus Supplement No. 1 dated May 22, 2017, and Prospectus Supplement No. 2 dated May 22, 2017) ENUMERAL BIOMEDICAL HOLDINGS, INC. 424B3 1 s106439424b3.htm 424B3 Filed Pursuant to Rule 424(b)(3) and Rule 424(c) Registration No. 333-216533 Prospectus Supplement No. 3 (To Prospectus filed on April 28, 2017, as supplemented by Prospectus Supplement No. 1 dated May 22, 2017, and Prospectus Supplement No. 2 dated May 22, 2017) ENUMERAL BIOMEDICAL HOLDINGS, INC. This Prospectus Supplement No. 3 supplements the information contained
June 2, 2017	8-K	Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 31, 2017 Enumeral Biomedical Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 000-55415 99-0376434 (State or Other Jurisdiction (Commission File (I.R
May 22, 2017	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 s1062838k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2017 Enumeral Biomedical Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 000-55415 99-0376434 (State or Other Jurisdicti
May 22, 2017	EX-99.1	Enumeral Reports First Quarter Financial Results Exhibit 99.1 Enumeral Reports First Quarter Financial Results CAMBRIDGE, Mass.?May 22, 2017?Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM) (?Enumeral? or the ?Company?), a biotechnology company focused on the discovery and advancement of next generation therapeutics in cancer and other diseases, today announced its financial results for the three months ended March 31, 2017. Recent Business High
May 22, 2017	424B3	Prospectus Supplement No. 2 (To Prospectus filed on April 28, 2017, as supplemented by Prospectus Supplement No. 1 dated May 22, 2017) ENUMERAL BIOMEDICAL HOLDINGS, INC. Filed Pursuant to Rule 424(b)(3) and Rule 424(c) Registration No. 333-216533 Prospectus Supplement No. 2 (To Prospectus filed on April 28, 2017, as supplemented by Prospectus Supplement No. 1 dated May 22, 2017) ENUMERAL BIOMEDICAL HOLDINGS, INC. This Prospectus Supplement No. 2 supplements the information contained in the Prospectus, dated as of April 28, 2017, as supplemented by Prospectus Suppl
May 22, 2017	10-Q	Enumeral Biomedical Holdings QUARTERLY REPORT (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2017. OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 000-55415 ENUMER
May 22, 2017	424B3	Prospectus Supplement No. 1 (To Prospectus filed on April 28, 2017) ENUMERAL BIOMEDICAL HOLDINGS, INC. Filed Pursuant to Rule 424(b)(3) and Rule 424(c) Registration No. 333-216533 Prospectus Supplement No. 1 (To Prospectus filed on April 28, 2017) ENUMERAL BIOMEDICAL HOLDINGS, INC. This Prospectus Supplement No. 1 supplements the information contained in the Prospectus, dated as of April 28, 2017, relating to the resale of up to 133,674,598 shares of our common stock by selling stockholders. This P
May 22, 2017	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 19, 2017 Enumeral Biomedical Holdings, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 000-55415 99-0376434 (State or other jurisdiction of incorporation) (Commis
May 15, 2017	NT 10-Q	Enumeral Biomedical Holdings NT 10-Q SEC FILE NUMBER 000-55415 CUSIP NUMBER 294017108 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
April 28, 2017	424B3	ENUMERAL BIOMEDICAL HOLDINGS, INC. 133,674,598 Shares Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-216533 ENUMERAL BIOMEDICAL HOLDINGS, INC. Prospectus 133,674,598 Shares Common Stock This prospectus relates to the resale of up to 133,674,598 shares of common stock, par value $0.001 per share (?Common Stock?), of Enumeral Biomedical Holdings, Inc. (?we,? ?Enumeral Biomedical,? or the ?Company?) held by certain selling stockholders, consistin
March 31, 2017	S-1/A	Enumeral Biomedical Holdings S-1/A As filed with the Securities and Exchange Commission on March 31, 2017 Registration No.
March 28, 2017	424B3	Prospectus Supplement No. 10 (To Prospectus filed on July 26, 2016, as supplemented by Prospectus Supplement No. 1 dated August 1, 2016, Prospectus Supplement No. 2 dated August 10, 2016, Prospectus Supplement No. 3 dated August 12, 2016 and Prospect Filed Pursuant to Rule 424(b)(3) and Rule 424(c) Registration No. 333-198847 Prospectus Supplement No. 10 (To Prospectus filed on July 26, 2016, as supplemented by Prospectus Supplement No. 1 dated August 1, 2016, Prospectus Supplement No. 2 dated August 10, 2016, Prospectus Supplement No. 3 dated August 12, 2016 and Prospectus Supplement No. 4 dated August 19, 2016, Prospectus Supplement No. 5 da
March 28, 2017	EX-99.1	Enumeral Reports Year End 2016 Financial Results Exhibit 99.1 Enumeral Reports Year End 2016 Financial Results CAMBRIDGE, Mass.?March 28, 2017?Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM) (?Enumeral? or the ?Company?), a biotechnology company focused on the discovery and advancement of next generation therapeutics in cancer and other diseases, today announced its financial results for the year ended December 31, 2016. ?Over the last several
March 28, 2017	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2017 Enumeral Biomedical Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 000-55415 99-0376434 (State or Other Jurisdiction (Commission File (I
March 28, 2017	10-K	Enumeral Biomedical Holdings 10-K (Annual Report) 10-K 1 s10562210k.htm 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe
March 28, 2017	EX-10.42	Form of Amended Placement Agent Warrant for Common Stock of Enumeral Biomedical Holdings, Inc. issued in connection with conversion of July 2016 Promissory Notes. Exhibit 10.42 Warrant Certificate No. NEITHER THE SECURITIES REPRESENTED HEREBY NOR THE SECURITIES ISSUABLE UPON THE EXERCISE OF THIS WARRANT HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY STATE SECURITIES LAWS, AND NEITHER SUCH SECURITIES NOR ANY INTEREST THEREIN MAY BE OFFERED, SOLD, PLEDGED, OR OTHERWISE TRANSFERRED UNLESS (1) A REGISTRATION STA
March 28, 2017	EX-10.7	Amendment No. 1 to Definitive License and Transfer Agreement, effective as of January 3, 2017, between Enumeral Biomedical Holdings, Inc., Pieris Pharmaceuticals, Inc., and Pieris Pharmaceuticals GmbH. Exhibit 10.7 AMENDMENT NO. 1 TO DEFINITIVE LICENSE AND TRANSFER AGREEMENT This Amendment No. 1 to Definitive License and Transfer Agreement (this “Amendment”), effective as of January 3, 2017 (the “Amendment Effective Date”), is by and between Enumeral Biomedical Holdings, Inc., a Delaware corporation with a place of business at 200 Cambridge Park Drive, Suite 2000, Cambridge, MA 02140 (“Enumeral”
March 28, 2017	EX-21.1	Subsidiaries of Enumeral Biomedical Holdings, Inc. Exhibit 21.1 List of Subsidiaries Name of Subsidiary Jurisdiction of Incorporation Enumeral Biomedical Corp. Delaware Enumeral Securities Corporation Delaware
March 8, 2017	S-1	Enumeral Biomedical Holdings S-1 As filed with the Securities and Exchange Commission on March 8, 2017 Registration No.
February 10, 2017	SC 13G	ENUM / Enumeral Biomedical Holdings, Inc. / PEIERLS E JEFFREY - ENUMERAL BIOMEDICAL HOLDINGS, INC. Passive Investment Converted by EDGARwiz SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Enumeral Biomedical Holdings, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 294017108 (CUSIP Number) December 31, 2016 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule purs
January 23, 2017	SC 13G	ENUM / Enumeral Biomedical Holdings, Inc. / SATTERFIELD THOMAS A JR - SC 13G Passive Investment SC 13G 1 d282781dsc13g.htm SC 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (Amendment No. )* Enumeral Biomedical Holdings, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 294017108 (CUSIP Number) J
January 23, 2017	EX-99.A	AGREEMENT FOR JOINT FILING OF SCHEDULE 13G EX-99.A Exhibit A AGREEMENT FOR JOINT FILING OF SCHEDULE 13G Thomas A. Satterfield, Jr. and A.G. Family L.P. hereby agree to file jointly the statement on Schedule 13G to which this Agreement for Joint Filing of Schedule 13G (this “Agreement”) is attached, as well as any amendments thereto which may be deemed necessary, pursuant to Rule 13d-1(k) under the Securities Exchange Act of 1934. Each of t
January 9, 2017	424B3	Prospectus Supplement No. 9 (To Prospectus filed on July 26, 2016, as supplemented by Prospectus Supplement No. 1 dated August 1, 2016, Prospectus Supplement No. 2 dated August 10, 2016, Prospectus Supplement No. 3 dated August 12, 2016 and Prospectu Filed Pursuant to Rule 424(b)(3) and Rule 424(c) Registration No. 333-198847 Prospectus Supplement No. 9 (To Prospectus filed on July 26, 2016, as supplemented by Prospectus Supplement No. 1 dated August 1, 2016, Prospectus Supplement No. 2 dated August 10, 2016, Prospectus Supplement No. 3 dated August 12, 2016 and Prospectus Supplement No. 4 dated August 19, 2016, Prospectus Supplement No. 5 dat
January 9, 2017	8-K	Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 s1050918k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2017 Enumeral Biomedical Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 000-55415 99-0376434 (State or Other Jurisdi
January 9, 2017	EX-99.2	Translating biological complexity into more powerful therapeutics January 2017 Exhibit 99.2 Translating biological complexity into more powerful therapeutics January 2017 Forward Looking Statements This presentation contains forward - looking statements that are based on the company?s current expectations, assumptions, estimates and projections about the company and the pharmaceutical industry . The company makes no representations about the accuracy of such statements estim
January 9, 2017	EX-99.1	Forward Looking Statements This presentation contains forward - looking statements that are based on the company’s current expectations, assumptions, estimates and projections about the company and the pharmaceutical industry . The company makes no r Exhibit 99.1 Enumeral Corporate Overview January 2017 OTCQB: ENUM Contact: Wael Fayad Chairman, President, and CEO 200 CambridgePark Drive Cambridge, MA 02140 [email protected] O: 617 - 500 - 1613 Forward Looking Statements This presentation contains forward - looking statements that are based on the company?s current expectations, assumptions, estimates and projections about the company and the p
December 12, 2016	424B3	Prospectus Supplement No. 8 (To Prospectus filed on July 26, 2016, as supplemented by Prospectus Supplement No. 1 dated August 1, 2016, Prospectus Supplement No. 2 dated August 10, 2016, Prospectus Supplement No. 3 dated August 12, 2016 and Prospectu Filed Pursuant to Rule 424(b)(3) and Rule 424(c) Registration No. 333-198847 Prospectus Supplement No. 8 (To Prospectus filed on July 26, 2016, as supplemented by Prospectus Supplement No. 1 dated August 1, 2016, Prospectus Supplement No. 2 dated August 10, 2016, Prospectus Supplement No. 3 dated August 12, 2016 and Prospectus Supplement No. 4 dated August 19, 2016, Prospectus Supplement No. 5 dat
December 12, 2016	EX-10.2	AMENDMENT TO AMENDED AND RESTATED WARRANTS TO PURCHASE STOCK Exhibit 10.1 AMENDMENT TO AMENDED AND RESTATED WARRANTS TO PURCHASE STOCK This Amendment (this ?Amendment?) to Amended and Restated Warrants to Purchase Stock is made and entered into effective as of the Expiration Date (as defined in this Amendment), by and between Enumeral Biomedical Holdings, Inc., a Delaware corporation (the ?Company?), and PacWest Bancorp (the ?Holder?). Capitalized terms use
December 12, 2016	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Unregistered Sales of Equity Securities, Financial Statements and Exhibits 8-K 1 s1049288k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2016 Enumeral Biomedical Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 000-55415 99-0376434 (State or Other Jurisd
December 12, 2016	EX-99.1	Enumeral Completes Successful Warrant Tender Offer and Receives $3.4 Million in Gross Proceeds Obtains Consent to Remove Anti-Dilution Protection of Outstanding Warrants and Continues to Deliver on Turnaround Plan Exhibit 99.1 Enumeral Completes Successful Warrant Tender Offer and Receives $3.4 Million in Gross Proceeds Obtains Consent to Remove Anti-Dilution Protection of Outstanding Warrants and Continues to Deliver on Turnaround Plan CAMBRIDGE, Mass.?December 12, 2016?Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM) (?Enumeral? or the ?Company?), a biotechnology company focused on the discovery and advan
December 12, 2016	SC TO-I/A	Enumeral Biomedical Holdings SC TO-I/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO (Amendment No. 5) TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 Enumeral Biomedical Holdings, Inc. (Name of Subject Company (Issuer) and Filing Person (Offeror)) WARRANTS TO PURCHASE COMMON STOCK (Title of Class of Securities) 294017108 (CUSIP Number of Common Stoc
December 5, 2016	SC TO-I/A	Enumeral Biomedical Holdings SC TO-I/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO (Amendment No. 4) TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 Enumeral Biomedical Holdings, Inc. (Name of Subject Company (Issuer) and Filing Person (Offeror)) WARRANTS TO PURCHASE COMMON STOCK (Title of Class of Securities) 294017108 (CUSIP Number of Common Stoc
November 29, 2016	SC TO-I/A	Enumeral Biomedical Holdings SC TO-I/A SC TO-I/A 1 s104811sctoia.htm SC TO-I/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO (Amendment No. 3) TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 Enumeral Biomedical Holdings, Inc. (Name of Subject Company (Issuer) and Filing Person (Offeror)) WARRANTS TO PURCHASE COMMON STOCK (Title of Class of Securities
November 29, 2016	8-K	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 29, 2016 Enumeral Biomedical Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware (State or Other Jurisdiction of Incorporation) 000-55415 (Commissi
November 22, 2016	SC TO-I/A	Enumeral Biomedical Holdings SC TO-I/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO (Amendment No. 2) TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 Enumeral Biomedical Holdings, Inc. (Name of Subject Company (Issuer) and Filing Person (Offeror)) WARRANTS TO PURCHASE COMMON STOCK (Title of Class of Securities) 294017108 (CUSIP Number of Common Stoc
November 10, 2016	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 s1046228k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2016 Enumeral Biomedical Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 000-55415 99-0376434 (State or Other Juris
November 10, 2016	EX-99.1	Enumeral Reports Third Quarter Financial Results EX-99.1 2 s104622ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Enumeral Reports Third Quarter Financial Results CAMBRIDGE, Mass.—November 10, 2016—Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM) (“Enumeral” or the “Company”), a biotechnology company focused on the discovery and development of novel antibody-based immunotherapies to help the immune system fight cancer and other diseases, today provided a b
November 10, 2016	SC TO-I/A	Enumeral Biomedical Holdings SC TO-I/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO (Amendment No. 1) TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 Enumeral Biomedical Holdings, Inc. (Name of Subject Company (Issuer) and Filing Person (Offeror)) WARRANTS TO PURCHASE COMMON STOCK (Title of Class of Securities) 294017108 (CUSIP Number of Common Stoc
November 10, 2016	424B3	Prospectus Supplement No. 7 (To Prospectus filed on July 26, 2016, as supplemented by Prospectus Supplement No. 1 dated August 1, 2016, Prospectus Supplement No. 2 dated August 10, 2016, Prospectus Supplement No. 3 dated August 12, 2016 and Prospectu Filed Pursuant to Rule 424(b)(3) and Rule 424(c) Registration No. 333-198847 Prospectus Supplement No. 7 (To Prospectus filed on July 26, 2016, as supplemented by Prospectus Supplement No. 1 dated August 1, 2016, Prospectus Supplement No. 2 dated August 10, 2016, Prospectus Supplement No. 3 dated August 12, 2016 and Prospectus Supplement No. 4 dated August 19, 2016, Prospectus Supplement No. 5 dat
November 10, 2016	EX-10.2	SUBSCRIPTION AGREEMENT Exhibit 10.2 SUBSCRIPTION AGREEMENT THIS SUBSCRIPTION AGREEMENT (this ?Agreement?), dated as of July 29, 2016, is entered into by and between Enumeral Biomedical Holdings, Inc., a Delaware corporation (the ?Company?), and the Buyer(s) set forth on the signature page(s) affixed hereto (individually, a ?Buyer? or collectively, the ?Buyers?). WITNESSETH: WHEREAS, the Company and the Buyer(s) are exec
November 10, 2016	10-Q	Enumeral Biomedical Holdings 10-Q (Quarterly Report) 10-Q 1 s10458010q.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2016. OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commissio
November 10, 2016	EX-4.1	12% SENIOR SECURED PROMISSORY NOTE ENUMERAL BIOMEDICAL HOLDINGS, INC. DUE July 29, 2017 Exhibit 4.1 For U.S. Investors: THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?). THESE SECURITIES MAY BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED ONLY (A) TO THE COMPANY, (B) OUTSIDE THE UNITED STATES IN COMPLIANCE WITH RULE 904 OF REGULATION S UNDER THE SECURITIES ACT, (C) IN COMPLIANCE WITH RULE 1
November 10, 2016	EX-10.1	KATALYST SECURITIES LLC 1330 AVENUE OF THE AMERICAS, 14TH FLOOR NEW YORK, NY 10019 Member: FINRA & SIPC PLACEMENT AGENCY AGREEMENT Exhibit 10.1 KATALYST SECURITIES LLC 1330 AVENUE OF THE AMERICAS, 14TH FLOOR NEW YORK, NY 10019 Member: FINRA & SIPC PLACEMENT AGENCY AGREEMENT June 21, 2016 Enumeral Biomedical Holdings, Inc. 200 Cambridge Park Drive, Suite 2000 Cambridge, MA 02140 Re: Private placement offering of 12% Senior Secured Promissory Notes To Whom It May Concern: This Placement Agency Agreement (?Agreement?) sets forth
November 10, 2016	EX-10.3	ESCROW AGREEMENT Exhibit 10.3 ESCROW AGREEMENT Escrow Agreement (the ?Escrow Agreement?), dated as of the effective date (the ?Effective Date?) set forth on Schedule 1 hereto (?Schedule 1?), by and among the corporation identified as the ?Company? on Schedule 1 hereto (the ?Company?), the limited liability company identified as the ?Depositor? on Schedule 1 hereto (the ?Depositor?), and Delaware Trust Company, as
November 10, 2016	EX-10.4	INTELLECTUAL PROPERTY SECURITY AGREEMENT Exhibit 10.4 INTELLECTUAL PROPERTY SECURITY AGREEMENT This Intellectual Property Security Agreement (this “Security Agreement”) is made as of July 29, 2016 by and among Enumeral Biomedical Holdings Inc. (the “Company”) and its subsidiary, Enumeral Biomedical Corp. (the “Subsidiary”), each a Delaware corporation, and each with offices at 200 CambridgePark Drive, Suite 2000, Cambridge, MA 02140 (col
November 10, 2016	EX-10.10	Enumeral Biomedical Holdings, Inc. Non-Qualified Stock Option Agreement Exhibit 10.10 Confidential portions of this document have been redacted and omitted pursuant to a Request for Confidential Treatment filed with the Securities and Exchange Commission (the "SEC") pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. The redacted and omitted portions are indicated with the notation “*” and have been filed separately with the SEC. Enumeral Bio
November 10, 2016	EX-10.11	Confidential portions of this document have been redacted and omitted pursuant to a Request for Confidential Treatment filed with the Securities and Exchange Commission (the "SEC") pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as Exhibit 10.11 Confidential portions of this document have been redacted and omitted pursuant to a Request for Confidential Treatment filed with the Securities and Exchange Commission (the "SEC") pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. The redacted and omitted portions are indicated with the notation “*” and have been filed separately with the SEC. AMENDMENT OF
November 10, 2016	EX-10.9	Enumeral Biomedical Holdings, Inc. 2014 Equity Incentive Plan Incentive Stock Option Agreement Exhibit 10.9 Confidential portions of this document have been redacted and omitted pursuant to a Request for Confidential Treatment filed with the Securities and Exchange Commission (the "SEC") pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. The redacted and omitted portions are indicated with the notation “*” and have been filed separately with the SEC. Enumeral Biom
November 10, 2016	EX-10.8	200 CambridgePark Drive · Suite 2000 · Cambridge, MA 02140 · O: 617.945.9146 EX-10.8 7 s104580ex10-8.htm EXHIBIT 10.8 Exhibit 10.8 Confidential portions of this document have been redacted and omitted pursuant to a Request for Confidential Treatment filed with the Securities and Exchange Commission (the "SEC") pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. The redacted and omitted portions are indicated with the notation “*” and have been fil
October 28, 2016	EX-99.1	Enumeral Overview October 2016 OTCQB: ENUM Exhibit 99.1 Enumeral Overview October 2016 OTCQB: ENUM Forward Looking Statements This presentation contains forward - looking statements that are based on the company?s current expectations, assumptions, estimates and projections about the company and the pharmaceutical industry . The company makes no representations about the accuracy of such statements estimates or projections . Forward - look
October 28, 2016	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2016 Enumeral Biomedical Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 000-55415 99-0376434 (State or Other Jurisdiction (Commission File
October 28, 2016	8-K	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2016 Enumeral Biomedical Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 000-55415 99-0376434 (State or Other Jurisdiction of Incorporation)
October 28, 2016	EX-99.A1A	ENUMERAL BIOMEDICAL HOLDINGS, INC. 200 Cambridgepark Drive, Suite 2000 Cambridge, MA 02140 Exhibit 99(a)(1)(A) October 28, 2016 ENUMERAL BIOMEDICAL HOLDINGS, INC. 200 Cambridgepark Drive, Suite 2000 Cambridge, MA 02140 To the Holders of the Original Warrants: This letter is to inform you that Enumeral Biomedical Holdings, Inc. (the ?Company?) is offering holders of certain warrants to purchase common stock of the Company, $0.001 par value per share (?Common Stock?), the opportunity to a
October 28, 2016	EX-99.A1B	OFFER TO AMEND AND EXERCISE WARRANTS TO PURCHASE COMMON STOCK ENUMERAL BIOMEDICAL HOLDINGS, INC. October 28, 2016 THE OFFER TO AMEND AND EXERCISE (AND ASSOCIATED WITHDRAWAL RIGHTS) WILL EXPIRE AT 5:00 P.M. (EASTERN TIME) ON NOVEMBER 29, 2016 UNLESS T Exhibit 99(a)(1)(B) NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THE TRANSACTION CONTEMPLATED HEREIN; PASSED UPON THE MERITS OR FAIRNESS OF THE TRANSACTION; OR PASSED UPON THE ADEQUACY OR ACCURACY OF THE DISCLOSURE IN THIS DOCUMENT.
October 28, 2016	SC TO-I	Enumeral Biomedical Holdings SC TO-I UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 Enumeral Biomedical Holdings, Inc. (Name of Subject Company (Issuer) and Filing Person (Offeror)) WARRANTS TO PURCHASE COMMON STOCK (Title of Class of Securities) (CUSIP Number of Common Stock Underlying Warrants) Wael
September 29, 2016	EX-24.1	POWER OF ATTORNEY Exhibit 24.1 POWER OF ATTORNEY Know all by these presents that the undersigned hereby constitutes and appoints each of Matthew A. Ebert and Kevin G. Sarney, or either of them signing individually, and with full power of substitution, the undersigned's true and lawful attorney-in-fact to: (1) prepare, execute in the undersigned?s name and on the undersigned?s behalf, and submit to the U.S. Securiti
September 23, 2016	424B3	Prospectus Supplement No. 6 (To Prospectus filed on July 26, 2016, as supplemented by Prospectus Supplement No. 1 dated August 1, 2016, Prospectus Supplement No. 2 dated August 10, 2016, Prospectus Supplement No. 3 dated August 12, 2016, Prospectus S Filed Pursuant to Rule 424(b)(3) and Rule 424(c) Registration No. 333-198847 Prospectus Supplement No. 6 (To Prospectus filed on July 26, 2016, as supplemented by Prospectus Supplement No. 1 dated August 1, 2016, Prospectus Supplement No. 2 dated August 10, 2016, Prospectus Supplement No. 3 dated August 12, 2016, Prospectus Supplement No. 4 dated August 19, 2016, and Prospectus Supplement No. 5 da
September 23, 2016	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events 8-K 1 s1041868k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 19, 2016 Enumeral Biomedical Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 000-55415 99-0376434 (State or Other Juri
September 23, 2016	EX-10.2	AMENDMENT NO. 1 TO SCIENTIFIC ADVISORY BOARD AGREEMENT EX-10.2 3 s104186ex10-2.htm EXHIBIT 10.2 Exhibit 10.2 AMENDMENT NO. 1 TO SCIENTIFIC ADVISORY BOARD AGREEMENT THIS AMENDMENT NO. 1 TO SCIENTIFIC ADVISORY BOARD AGREEMENT (the “Amendment”), is dated as of September 21, 2016, by and between Enumeral Biomedical Holdings, Inc., a Delaware corporation (with its subsidiaries, the “Company”), and Barry Buckland, Ph.D. (the “Advisor”). This Amendment amend
September 23, 2016	EX-99.1	Enumeral Appoints Wael Fayad as Chairman, President and Chief Executive Officer EX-99.1 4 s104186ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Enumeral Appoints Wael Fayad as Chairman, President and Chief Executive Officer CAMBRIDGE, Mass.—September 22, 2016—Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM) (“Enumeral” or the “Company”), a biotechnology company focused on the discovery and development of novel antibody-based immunotherapies to help the immune system fight cancer and ot
September 23, 2016	EX-10.1	September 21, 2016 EX-10.1 2 s104186ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 September 21, 2016 John J. Rydzewski c/o Enumeral Biomedical Holdings, Inc. 200 CambridgePark Drive, Suite 2000 Cambridge, MA 02140 Dear John: This letter agreement (the “Letter Agreement”) confirms that your employment with Enumeral Biomedical Holdings, Inc. (with its subsidiaries, the “Company”) has ceased effective September 21, 2016 and set
September 16, 2016	424B3	Prospectus Supplement No. 5 (To Prospectus filed on July 26, 2016, as supplemented by Prospectus Supplement No. 1 dated August 1, 2016, Prospectus Supplement No. 2 dated August 10, 2016, Prospectus Supplement No. 3 dated August 12, 2016, and Prospect Filed Pursuant to Rule 424(b)(3) and Rule 424(c) Registration No. 333-198847 Prospectus Supplement No. 5 (To Prospectus filed on July 26, 2016, as supplemented by Prospectus Supplement No. 1 dated August 1, 2016, Prospectus Supplement No. 2 dated August 10, 2016, Prospectus Supplement No. 3 dated August 12, 2016, and Prospectus Supplement No. 4 dated August 19, 2016) ENUMERAL BIOMEDICAL HOLDINGS,
September 16, 2016	8-K	Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 13, 2016 Enumeral Biomedical Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 000-55415 99-0376434 (State or Other Jurisdiction of Incorporatio
August 19, 2016	424B3	Prospectus Supplement No. 4 (To Prospectus filed on July 26, 2016, as supplemented by Prospectus Supplement No. 1 dated August 1, 2016, Prospectus Supplement No. 2 dated August 10, 2016, and Prospectus Supplement No. 3 dated August 12, 2016) ENUMERAL Filed Pursuant to Rule 424(b)(3) and Rule 424(c) Registration No. 333-198847 Prospectus Supplement No. 4 (To Prospectus filed on July 26, 2016, as supplemented by Prospectus Supplement No. 1 dated August 1, 2016, Prospectus Supplement No. 2 dated August 10, 2016, and Prospectus Supplement No. 3 dated August 12, 2016) ENUMERAL BIOMEDICAL HOLDINGS, INC. This Prospectus Supplement No. 4 supplements t
August 19, 2016	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8-K 1 s1039638k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 17, 2016 Enumeral Biomedical Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware (State or Other Jurisdiction of Incorporatio
August 19, 2016	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8-K 1 s1039638k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 17, 2016 Enumeral Biomedical Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware (State or Other Jurisdiction of Incorporatio
August 12, 2016	EX-99.1	Enumeral Reports Second Quarter Financial Results Exhibit 99.1 Enumeral Reports Second Quarter Financial Results CAMBRIDGE, Mass.?August 12, 2016?Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM) (?Enumeral? or the ?Company?), a biotechnology company focused on the discovery and development of novel antibody-based immunotherapies to help the immune system fight cancer and other diseases, today announced its financial results for the quarter ended
August 12, 2016	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2016 Enumeral Biomedical Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 000-55415 99-0376434 (State or Other Jurisdiction (Commission File (
August 12, 2016	424B3	Prospectus Supplement No. 3 (To Prospectus filed on July 26, 2016, as supplemented by Prospectus Supplement No. 1 dated August 1, 2016 and Prospectus Supplement No. 2 dated August 10, 2016) ENUMERAL BIOMEDICAL HOLDINGS, INC. Filed Pursuant to Rule 424(b)(3) and Rule 424(c) Registration No. 333-198847 Prospectus Supplement No. 3 (To Prospectus filed on July 26, 2016, as supplemented by Prospectus Supplement No. 1 dated August 1, 2016 and Prospectus Supplement No. 2 dated August 10, 2016) ENUMERAL BIOMEDICAL HOLDINGS, INC. This Prospectus Supplement No. 3 supplements the information contained in the Prospectus, dated as
August 12, 2016	EX-10.1	DEFINITIVE LICENSE AND TRANSFER AGREEMENT Exhibit 10.1 Confidential portions of this document have been redacted and omitted pursuant to a Request for Confidential Treatment filed with the Securities and Exchange Commission (the “SEC”) pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. The redacted and omitted portions are indicated with the notation “*” and have been filed separately with the SEC. DEFINITIVE LI
August 12, 2016	10-Q	Enumeral Biomedical Holdings 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2016. OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 000-55415 ENUMERA
August 10, 2016	424B3	Prospectus Supplement No. 2 (To Prospectus filed on July 26, 2016, as supplemented by Prospectus Supplement No. 1 dated August 1, 2016) ENUMERAL BIOMEDICAL HOLDINGS, INC. Filed Pursuant to Rule 424(b)(3) and Rule 424(c) Registration No. 333-198847 Prospectus Supplement No. 2 (To Prospectus filed on July 26, 2016, as supplemented by Prospectus Supplement No. 1 dated August 1, 2016) ENUMERAL BIOMEDICAL HOLDINGS, INC. This Prospectus Supplement No. 2 supplements the information contained in the Prospectus, dated as of July 26, 2016, as amended by Prospectus Supplement
August 10, 2016	EX-10.1	August 4, 2016 Exhibit 10.1 August 4, 2016 Arthur H. Tinkelenberg, Ph.D. c/o Enumeral Biomedical Holdings, Inc. 200 CambridgePark Drive, Suite 2000 Cambridge, MA 02140 Dear Arthur: This letter agreement (the ?Letter Agreement?) confirms that your employment with Enumeral Biomedical Holdings, Inc. (with its subsidiaries, the ?Company?) has ceased effective July 28, 2016 and sets forth the terms of your separation
August 10, 2016	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2016 Enumeral Biomedical Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware (State or Other Jurisdiction of Incorporation) 000-55415 (Commission
August 1, 2016	424B3	Prospectus Supplement No. 1 (To Prospectus filed on July 26, 2016) ENUMERAL BIOMEDICAL HOLDINGS, INC. 424B3 1 s103791424b3.htm 424B3 Filed Pursuant to Rule 424(b)(3) and Rule 424(c) Registration No. 333-198847 Prospectus Supplement No. 1 (To Prospectus filed on July 26, 2016) ENUMERAL BIOMEDICAL HOLDINGS, INC. This Prospectus Supplement No. 1 supplements the information contained in the Prospectus, dated as of July 26, 2016, relating to the resale of up to 47,674,386 shares of our common stock by
August 1, 2016	EX-99.1	Enumeral Announces Sale of 12% Senior Secured Promissory Notes Exhibit 99.1 Enumeral Announces Sale of 12% Senior Secured Promissory Notes CAMBRIDGE, Mass.?August 1, 2016?Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM) (?Enumeral? or the ?Company?), a biotechnology company focused on the discovery and development of novel antibody-based immunotherapies to help the immune system fight cancer and other diseases, today announced that on July 29, 2016 the Compan
August 1, 2016	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2016 Enumeral Biomedical Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware (State or Other Jurisdiction of Incorporation) 000-55415 (Commission F
July 26, 2016	424B3	ENUMERAL BIOMEDICAL HOLDINGS, INC. 47,674,386 Shares Common Stock 424B3 1 s103739424b3.htm 424(B)(3) Filed Pursuant to Rule 424(b)(3) Registration No. 333-198847 ENUMERAL BIOMEDICAL HOLDINGS, INC. Prospectus 47,674,386 Shares Common Stock This prospectus relates to the resale of up to 47,674,386 shares of common stock, par value $0.001 per share (“Common Stock”), of Enumeral Biomedical Holdings, Inc. (“we” or the “Company”) held by certain selling stockholders,
June 30, 2016	POS AM	Enumeral Biomedical Holdings POS AM As filed with the Securities and Exchange Commission on June 30, 2016 Registration No.
June 28, 2016	10-Q/A	Enumeral Biomedical Holdings AMENDED QUARTERLY REPORT (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A (Amendment No. 1) (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2016. OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Numb
June 28, 2016	EX-10.2	LICENSE AND TRANSFER AGREEMENT EX-10.2 2 s103584ex10-2.htm EXHIBIT 10-2 Exhibit 10.2 Confidential portions of this document have been redacted and omitted pursuant to a Request for Confidential Treatment filed with the Securities and Exchange Commission (the "SEC") pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. The redacted and omitted portions are indicated with the notation “*” and have been fil
June 6, 2016	424B3	Prospectus Supplement No. 23 (To Prospectus filed on July 6, 2015, as supplemented by Prospectus Supplement No. 1 dated July 14, 2015, Prospectus Supplement No. 2 dated July 28, 2015, Prospectus Supplement No. 3 dated August 4, 2015, Prospectus Suppl Filed Pursuant to Rule 424(b)(3) and Rule 424(c) Registration No. 333-198847 Prospectus Supplement No. 23 (To Prospectus filed on July 6, 2015, as supplemented by Prospectus Supplement No. 1 dated July 14, 2015, Prospectus Supplement No. 2 dated July 28, 2015, Prospectus Supplement No. 3 dated August 4, 2015, Prospectus Supplement No. 4 dated August 12, 2015, Prospectus Supplement No. 5 dated Sept
June 6, 2016	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2016 Enumeral Biomedical Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware (State or Other Jurisdiction of Incorporation) 000-55415 (Commission Fi
June 6, 2016	EX-99.1	Enumeral Receives Maintenance Fee to Continue License Agreement with Pieris and Enters into Definitive License Agreement Exhibit 99.1 Enumeral Receives Maintenance Fee to Continue License Agreement with Pieris and Enters into Definitive License Agreement CAMBRIDGE, Mass.?June 6, 2016?Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM) (?Enumeral? or the ?Company?), a biotechnology company focused on discovering and developing novel antibody-based immunotherapies to help the immune system fight cancer and other diseases
May 13, 2016	EX-99.1	Enumeral Overview May 2016 Exhibit 99.1 Enumeral Overview May 2016 Forward Looking Statements OTC QB: ENUM THIS PRESENTATION CONTAINS FORWARD - LOOKING STATEMENTS THAT ARE BASED ON THE COMPANY’S CURRENT EXPECTATIONS, ASSUMPTIONS, ESTIMATES AND PROJECTIONS ABOUT THE COMPANY AND THE PHARMACEUTICAL INDUSTRY . THE COMPANY MAKES NO REPRESENTATIONS ABOUT THE ACCURACY OF SUCH STATEMENTS ESTIMATES OR PROJECTIONS . FORWARD - LOOKING
May 13, 2016	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2016 Enumeral Biomedical Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 000-55415 99-0376434 (State or Other Jurisdiction (Commission File (I.R
May 13, 2016	EX-99.1	Enumeral Reports First Quarter Financial Results Exhibit 99.1 Enumeral Reports First Quarter Financial Results CAMBRIDGE, Mass.-May 13, 2016-Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM) (?Enumeral? or the ?Company?), a biotechnology company focused on the discovery and development of novel antibody-based immunotherapies to help the immune system fight cancer and other diseases, today announced its financial results for the three months ended
May 13, 2016	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2016 Enumeral Biomedical Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 000-55415 99-0376434 (State or Other Jurisdiction of Incorporation) (Co
May 13, 2016	424B3	Prospectus Supplement No. 22 (To Prospectus filed on July 6, 2015, as supplemented by Prospectus Supplement No. 1 dated July 14, 2015, Prospectus Supplement No. 2 dated July 28, 2015, Prospectus Supplement No. 3 dated August 4, 2015, Prospectus Suppl Filed Pursuant to Rule 424(b)(3) and Rule 424(c) Registration No. 333-198847 Prospectus Supplement No. 22 (To Prospectus filed on July 6, 2015, as supplemented by Prospectus Supplement No. 1 dated July 14, 2015, Prospectus Supplement No. 2 dated July 28, 2015, Prospectus Supplement No. 3 dated August 4, 2015, Prospectus Supplement No. 4 dated August 12, 2015, Prospectus Supplement No. 5 dated Sept
May 13, 2016	EX-10.2	LICENSE AND TRANSFER AGREEMENT Exhibit 10.2 Confidential portions of this document have been redacted and omitted pursuant to a Request for Confidential Treatment filed with the Securities and Exchange Commission (the "SEC") pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. The redacted and omitted portions are indicated with the notation “*” and have been filed separately with the SEC. LICENSE AND T
May 13, 2016	10-Q	Enumeral Biomedical Holdings FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2016. OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 000-55415 ENUMER
May 13, 2016	EX-10.1	FOURTH AMENDMENT EX-10.1 2 s103227ex10-1.htm EXHIBIT 10-1 Exhibit 10.1 Confidential portions of this document have been redacted and omitted pursuant to a Request for Confidential Treatment filed with the Securities and Exchange Commission (the "SEC") pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. The redacted and omitted portions are indicated with the notation “*” and have been fil
April 27, 2016	10-K/A	Enumeral Biomedical Holdings FORM 10-K/A (Annual Report) 10-K/A 1 s10307210ka.htm FORM 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period
April 18, 2016	424B3	Prospectus Supplement No. 21 (To Prospectus filed on July 6, 2015, as supplemented by Prospectus Supplement No. 1 dated July 14, 2015, Prospectus Supplement No. 2 dated July 28, 2015, Prospectus Supplement No. 3 dated August 4, 2015, Prospectus Suppl Filed Pursuant to Rule 424(b)(3) and Rule 424(c) Registration No. 333-198847 Prospectus Supplement No. 21 (To Prospectus filed on July 6, 2015, as supplemented by Prospectus Supplement No. 1 dated July 14, 2015, Prospectus Supplement No. 2 dated July 28, 2015, Prospectus Supplement No. 3 dated August 4, 2015, Prospectus Supplement No. 4 dated August 12, 2015, Prospectus Supplement No. 5 dated Sept
April 18, 2016	8-K	Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 s1030398k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 18, 2016 Enumeral Biomedical Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 000-55415 99-0376434 (State or Other Jurisdic
April 18, 2016	EX-99.1	EX-99.1 Exhibit 99.1 N i v o l u m a b - 2 0 3 8 8 D 4 - 2 ( 2 0 u g / m L ) 3 8 8 D 4 - 3 ( 2 0 u g / m L ) 2 4 4 C 8 - 1 ( 2 0 u g / m L ) 2 4 4 C 8 - 2 ( 2 0 u g / m L ) 2 4 4 C 8 - 3 ( 2 0 u g / m L ) 0 500 1000 1500 IL-12 p70 p g / m l Discovery, C haracterization and Development of a New C lass of T herapeutic A nti - PD - 1 A ntibody Abstract Blockade of immune checkpoint proteins (IC), such as PD
April 18, 2016	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events 8-K 1 s1030388k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 18, 2016 Enumeral Biomedical Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 000-55415 99-0376434 (State or Other Jurisdic
April 18, 2016	EX-99.1	Enumeral and Pieris Pharmaceuticals Enter into License and Transfer Agreement EX-99.1 2 s103038ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Enumeral and Pieris Pharmaceuticals Enter into License and Transfer Agreement CAMBRIDGE, Mass.—April 18, 2016—Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM) (“Enumeral” or the “Company”), a biotechnology company focused on discovering and developing novel antibody-based immunotherapies to help the immune system fight cancer and other diseases
April 15, 2016	424B3	Prospectus Supplement No. 20 (To Prospectus filed on July 6, 2015, as supplemented by Prospectus Supplement No. 1 dated July 14, 2015, Prospectus Supplement No. 2 dated July 28, 2015, Prospectus Supplement No. 3 dated August 4, 2015, Prospectus Suppl Filed Pursuant to Rule 424(b)(3) and Rule 424(c) Registration No. 333-198847 Prospectus Supplement No. 20 (To Prospectus filed on July 6, 2015, as supplemented by Prospectus Supplement No. 1 dated July 14, 2015, Prospectus Supplement No. 2 dated July 28, 2015, Prospectus Supplement No. 3 dated August 4, 2015, Prospectus Supplement No. 4 dated August 12, 2015, Prospectus Supplement No. 5 dated Sept
April 15, 2016	8-K	Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 14, 2016 Enumeral Biomedical Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 000-55415 99-0376434 (State or Other Jurisdiction of Incorporation) (
March 30, 2016	424B3	Prospectus Supplement No. 19 (To Prospectus filed on July 6, 2015, as supplemented by Prospectus Supplement No. 1 dated July 14, 2015, Prospectus Supplement No. 2 dated July 28, 2015, Prospectus Supplement No. 3 dated August 4, 2015, Prospectus Suppl Filed Pursuant to Rule 424(b)(3) and Rule 424(c) Registration No. 333-198847 Prospectus Supplement No. 19 (To Prospectus filed on July 6, 2015, as supplemented by Prospectus Supplement No. 1 dated July 14, 2015, Prospectus Supplement No. 2 dated July 28, 2015, Prospectus Supplement No. 3 dated August 4, 2015, Prospectus Supplement No. 4 dated August 12, 2015, Prospectus Supplement No. 5 dated Sept
March 30, 2016	8-K	Enumeral Biomedical Holdings FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2016 Enumeral Biomedical Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 000-55415 99-0376434 (State or Other Jurisdiction (Commission File (I
March 30, 2016	EX-99.1	Enumeral Reports Fourth Quarter and Year-End 2015 Financial Results Exhibit 99.1 Enumeral Reports Fourth Quarter and Year-End 2015 Financial Results CAMBRIDGE, Mass.?March 30, 2016?Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM) (?Enumeral? or the ?Company?), a biotechnology company focused on the discovery and development of novel therapeutics that help the immune system fight cancer and other diseases, today announced its financial results for the three months
March 30, 2016	10-K	Enumeral Biomedical Holdings FORM 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-55415 ENUMERAL BIOME
March 30, 2016	EX-10.31	COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENT BY AND BETWEEN ENUMERAL BIOMEDICAL HOLDINGS, INC. THE UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER January 11, 2016 TABLE OF CONTENTS Exhibit 10.31 Confidential portions of this document have been redacted and omitted pursuant to a Request for Confidential Treatment filed with the Securities and Exchange Commission (the "SEC") pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. The redacted and omitted portions are indicated with the notation ?*? and have been filed separately with the SEC. COLLABORATIV
March 30, 2016	EX-21.1	List of Subsidiaries Exhibit 21.1 List of Subsidiaries Name of Subsidiary Jurisdiction of Incorporation Enumeral Biomedical Corp. Delaware Enumeral Securities Corporation Delaware
March 30, 2016	EX-10.35	AMENDMENT NO. 1 TO STUDY AGREEMENT Merck Sharp & Dohme Corp. Enumeral Biomedical Holdings Inc. Exhibit 10.35 Confidential portions of this document have been redacted and omitted pursuant to a Request for Confidential Treatment filed with the Securities and Exchange Commission (the "SEC") pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. The redacted and omitted portions are indicated with the notation “*” and have been filed separately with the SEC. AMENDMENT NO
March 30, 2016	EX-10.38	200 CambridgePark Drive · Suite 2000 · Cambridge, MA 02140 · O: 617.945.9146 Exhibit 10.38 Arthur H. Tinkelenberg, Ph.D. President & CEO Enumeral Biomedical Holdings, Inc. March 24, 2016 Anhco Nguyen, Ph.D. c/o Enumeral Biomedical Holdings, Inc. 200 CambridgePark Drive, Suite 2000 Cambridge, MA 02140 Dear Cokey: Enumeral Biomedical Holdings, Inc. (with its subsidiaries, “Enumeral” or the “Company”) desires to continue to employ you as the Company’s Vice President of Resear
March 30, 2016	EX-10.37	200 CambridgePark Drive · Suite 2000 · Cambridge, MA 02140 · O: 617.945.9146 Exhibit 10.37 Arthur H. Tinkelenberg, Ph.D. President & CEO Enumeral Biomedical Holdings, Inc. March 24, 2016 Kevin G. Sarney c/o Enumeral Biomedical Holdings, Inc. 200 CambridgePark Drive, Suite 2000 Cambridge, MA 02140 Dear Kevin: Enumeral Biomedical Holdings, Inc. (with its subsidiaries, “Enumeral” or the “Company”) desires to continue to employ you as the Company’s Vice President of Finance, C
March 11, 2016	424B3	Prospectus Supplement No. 18 (To Prospectus filed on July 6, 2015, as supplemented by Prospectus Supplement No. 1 dated July 14, 2015, Prospectus Supplement No. 2 dated July 28, 2015, Prospectus Supplement No. 3 dated August 4, 2015, Prospectus Suppl Filed Pursuant to Rule 424(b)(3) and Rule 424(c) Registration No. 333-198847 Prospectus Supplement No. 18 (To Prospectus filed on July 6, 2015, as supplemented by Prospectus Supplement No. 1 dated July 14, 2015, Prospectus Supplement No. 2 dated July 28, 2015, Prospectus Supplement No. 3 dated August 4, 2015, Prospectus Supplement No. 4 dated August 12, 2015, Prospectus Supplement No. 5 dated Sept
March 11, 2016	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2016 Enumeral Biomedical Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 000-55415 99-0376434 (State or Other Jurisdiction (Commission File (I
March 11, 2016	EX-99.1	Corporate Overview March 2016 Exhibit 99.1 Corporate Overview March 2016 Company Highlights ? Enumeral is an antibody immuno - oncology company based on technology developed at Harvard and MIT ? Enumeral?s differentiated PD - 1 antagonist C8 has potential to become best - in - class cancer immunotherapy ? Novel mechanism of binding leads to in vitro enhanced activity ? Strong IP Position ? Fast - to - market development strate
February 16, 2016	SC 13G	ENUM / Enumeral Biomedical Holdings, Inc. / Tompkins Mark N. - SC 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 ENUMERAL BIOMEDICAL HOLDINGS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 294017108 (CUSIP Number) December 31, 2015 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: o
January 11, 2016	EX-99.1	Enumeral and MD Anderson Enter Into Collaborative Research and Development Agreement Strategic Collaboration Aims to Discover and Develop Potentially Novel Antibodies Against Specified Targets for Immunotherapy Exhibit 99.1 Enumeral and MD Anderson Enter Into Collaborative Research and Development Agreement Strategic Collaboration Aims to Discover and Develop Potentially Novel Antibodies Against Specified Targets for Immunotherapy CAMBRIDGE, Mass. and HOUSTON, Texas?January 11, 2016?Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM), today announced that it has entered into a Collaborative Research and Dev
January 11, 2016	8-K	Enumeral Biomedical Holdings 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2016 Enumeral Biomedical Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 000-55415 99-0376434 (State or Other Jurisdiction of Incorporation)
January 11, 2016	EX-99.1	EX-99.1 Exhibit 99.1 B Discovery and Functional Characterization of Novel Anti-PD-1 Antibodies Using Ex VivoCell-Based Assays, Single-Cell Immunoprofiling, and In Vivo Studies in Humanized Mice Abstract Given recent approvals of anti-PD-1 inhibitors Keytruda (pembrolizumab)andOpdivo(nivolumab)fortreatmentofmetastatic melanomaandnon-smallcelllungcancerNSCLC,weaskedwhether additionalanti-PD-1inhibitorswithd
January 11, 2016	8-K	Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 s1024538k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2016 Enumeral Biomedical Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 000-55415 99-0376434 (State or Other Jurisdi
January 11, 2016	424B3	Prospectus Supplement No. 17 (To Prospectus filed on July 6, 2015, as supplemented by Prospectus Supplement No. 1 dated July 14, 2015, Prospectus Supplement No. 2 dated July 28, 2015, Prospectus Supplement No. 3 dated August 4, 2015, Prospectus Suppl Filed Pursuant to Rule 424(b)(3) and Rule 424(c) Registration No. 333-198847 Prospectus Supplement No. 17 (To Prospectus filed on July 6, 2015, as supplemented by Prospectus Supplement No. 1 dated July 14, 2015, Prospectus Supplement No. 2 dated July 28, 2015, Prospectus Supplement No. 3 dated August 4, 2015, Prospectus Supplement No. 4 dated August 12, 2015, Prospectus Supplement No. 5 dated Sept
January 11, 2016	424B3	Prospectus Supplement No. 16 (To Prospectus filed on July 6, 2015, as supplemented by Prospectus Supplement No. 1 dated July 14, 2015, Prospectus Supplement No. 2 dated July 28, 2015, Prospectus Supplement No. 3 dated August 4, 2015, Prospectus Suppl Filed Pursuant to Rule 424(b)(3) and Rule 424(c) Registration No. 333-198847 Prospectus Supplement No. 16 (To Prospectus filed on July 6, 2015, as supplemented by Prospectus Supplement No. 1 dated July 14, 2015, Prospectus Supplement No. 2 dated July 28, 2015, Prospectus Supplement No. 3 dated August 4, 2015, Prospectus Supplement No. 4 dated August 12, 2015, Prospectus Supplement No. 5 dated Sept
January 11, 2016	EX-99.2	1sedforTCRsequencing.WedescribeamethodtomatchTCR sequenceswithTcellfunctionalprofilesthatincludescellsurface markers(e.g.CD3,CD4,CD8,TIGIT,PD-1)andsecretedcytokines (e.g. IL-6, TNF-a, IFN-?). Our method uses the proprietary Enumeralsinglecellplatform Exhibit 99.2 1sedforTCRsequencing.WedescribeamethodtomatchTCR sequenceswithTcellfunctionalprofilesthatincludescellsurface markers(e.g.CD3,CD4,CD8,TIGIT,PD-1)andsecretedcytokines (e.g. IL-6, TNF-a, IFN-?). Our method uses the proprietary EnumeralsinglecellplatformforbothTcellfunctionalprofiling andisolationofsingleTcellsofinterestforTCRsequencing.Here wedemonstratethatthismethodcanbeappliedtoTcells
December 8, 2015	424B3	Prospectus Supplement No. 15 (To Prospectus filed on July 6, 2015, as supplemented by Prospectus Supplement No. 1 dated July 14, 2015, Prospectus Supplement No. 2 dated July 28, 2015, Prospectus Supplement No. 3 dated August 4, 2015, Prospectus Suppl Filed Pursuant to Rule 424(b)(3) and Rule 424(c) Registration No. 333-198847 Prospectus Supplement No. 15 (To Prospectus filed on July 6, 2015, as supplemented by Prospectus Supplement No. 1 dated July 14, 2015, Prospectus Supplement No. 2 dated July 28, 2015, Prospectus Supplement No. 3 dated August 4, 2015, Prospectus Supplement No. 4 dated August 12, 2015, Prospectus Supplement No. 5 dated Sept
December 8, 2015	EX-99.1	Oppenheimer 26 th Annual Healthcare Conference December 8, 2015 Exhibit 99.1 Oppenheimer 26 th Annual Healthcare Conference December 8, 2015 Forward Looking Statements OTC QB: ENUM THIS PRESENTATIONCONTAINS FORWARD-LOOKING STATEMENTSTHATARE BASED ON THECOMPANY?SCURRENTEXPECTATIONS,ASSUMPTIONS,ESTIMATESANDPROJECTIONS ABOUTTHECOMPANYANDTHEPHARMACEUTICAL INDUSTRY.THECOMPANYMAKESNO REPRESENTATIONS ABOUT THE ACCURACY OF SUCH STATEMENTS ESTIMATES OR PROJECTIONS. FOR
December 8, 2015	8-K	Enumeral Biomedical Holdings 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 8, 2015 Enumeral Biomedical Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 000-55415 99-0376434 (State or Other Jurisdiction of Incorporation)
December 1, 2015	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2015 Enumeral Biomedical Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 000-55415 99-0376434 (State or Other Jurisdiction (Commission File
December 1, 2015	424B3	Prospectus Supplement No. 14 (To Prospectus filed on July 6, 2015, as supplemented by Prospectus Supplement No. 1 dated July 14, 2015, Prospectus Supplement No. 2 dated July 28, 2015, Prospectus Supplement No. 3 dated August 4, 2015, Prospectus Suppl Filed Pursuant to Rule 424(b)(3) and Rule 424(c) Registration No. 333-198847 Prospectus Supplement No. 14 (To Prospectus filed on July 6, 2015, as supplemented by Prospectus Supplement No. 1 dated July 14, 2015, Prospectus Supplement No. 2 dated July 28, 2015, Prospectus Supplement No. 3 dated August 4, 2015, Prospectus Supplement No. 4 dated August 12, 2015, Prospectus Supplement No. 5 dated Sept
December 1, 2015	EX-99.1	Research and Development Program Update December 1, 2015 Research and Development Program Update December 1, 2015 Agenda ? Preclinical animal model studies ? Ex vivo lung biopsy studies 2 Hu-NSG PDX study outline (Lung LG1306) 3 NSG PDX tumor bearing mice Hu-NSG (12 week post CD34+ engraftment (>25% human CD45+) Harvest tumor fragments and trocar into recipients ~ 2-3 weeks for tumor graft growth to 100 mm3 size Trocar date is depending on # of tumor be
November 18, 2015	8-K	Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 s1022178k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 18, 2015 Enumeral Biomedical Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 000-55415 99-0376434 (State or Other Juris
November 18, 2015	EX-99.1	EnumeralPD-1 Program Update: Differentiated Anti-PD-1 Antibody Functional Characterization in Ex VivoHuman Lung Biopsy Assays November 18, 2015 Exhibit 99.1 EnumeralPD-1 Program Update: Differentiated Anti-PD-1 Antibody Functional Characterization in Ex VivoHuman Lung Biopsy Assays November 18, 2015 Background ? Enumeraluses a unique single cell technology platform and approach to identify functionally differentiated antibody candidates ? Enumeralhas identified two classes of anti-PD-1 antibodies with distinct modes of binding to PD-1 ? B
November 18, 2015	424B3	Prospectus Supplement No. 13 (To Prospectus filed on July 6, 2015, as supplemented by Prospectus Supplement No. 1 dated July 14, 2015, Prospectus Supplement No. 2 dated July 28, 2015, Prospectus Supplement No. 3 dated August 4, 2015, Prospectus Suppl Filed Pursuant to Rule 424(b)(3) and Rule 424(c) Registration No. 333-198847 Prospectus Supplement No. 13 (To Prospectus filed on July 6, 2015, as supplemented by Prospectus Supplement No. 1 dated July 14, 2015, Prospectus Supplement No. 2 dated July 28, 2015, Prospectus Supplement No. 3 dated August 4, 2015, Prospectus Supplement No. 4 dated August 12, 2015, Prospectus Supplement No. 5 dated Sept
November 10, 2015	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 s1021518k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2015 Enumeral Biomedical Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 000-55415 99-0376434 (State or Other
November 10, 2015	EX-99.1	Enumeral Reports Third Quarter 2015 Financial Results and Provides Corporate Update Exhibit 99.1 Enumeral Reports Third Quarter 2015 Financial Results and Provides Corporate Update CAMBRIDGE, Mass.?November 10, 2015-Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM) (?Enumeral? or the ?Company?), a biotechnology company focused on discovering and developing novel antibody immunotherapies that help the immune system fight cancer and other diseases, today reported financial results f
November 10, 2015	424B3	Prospectus Supplement No. 12 (To Prospectus filed on July 6, 2015, as supplemented by Prospectus Supplement No. 1 dated July 14, 2015, Prospectus Supplement No. 2 dated July 28, 2015, Prospectus Supplement No. 3 dated August 4, 2015, Prospectus Suppl 424B3 1 s102156424b3.htm 424B3 Filed Pursuant to Rule 424(b)(3) and Rule 424(c) Registration No. 333-198847 Prospectus Supplement No. 12 (To Prospectus filed on July 6, 2015, as supplemented by Prospectus Supplement No. 1 dated July 14, 2015, Prospectus Supplement No. 2 dated July 28, 2015, Prospectus Supplement No. 3 dated August 4, 2015, Prospectus Supplement No. 4 dated August 12, 2015, Prospec
November 3, 2015	424B3	Prospectus Supplement No. 11 (To Prospectus filed on July 6, 2015, as supplemented by Prospectus Supplement No. 1 dated July 14, 2015, Prospectus Supplement No. 2 dated July 28, 2015, Prospectus Supplement No. 3 dated August 4, 2015, Prospectus Suppl Filed Pursuant to Rule 424(b)(3) and Rule 424(c) Registration No. 333-198847 Prospectus Supplement No. 11 (To Prospectus filed on July 6, 2015, as supplemented by Prospectus Supplement No. 1 dated July 14, 2015, Prospectus Supplement No. 2 dated July 28, 2015, Prospectus Supplement No. 3 dated August 4, 2015, Prospectus Supplement No. 4 dated August 12, 2015, Prospectus Supplement No. 5 dated Sept
November 3, 2015	8-K	Enumeral Biomedical Holdings 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2015 Enumeral Biomedical Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 000-55415 99-0376434 (State or Other Jurisdiction (Commission File
November 3, 2015	EX-99.1	Enumeral PD - 1 Program Update: Differentiated Anti - PD - 1 Antibody Elicits Higher T Cell Activation in Ex Vivo Human Assays than a Currently Marketed Anti - PD - 1 Antibody November 3, 2015 Exhibit 99.1 Enumeral PD - 1 Program Update: Differentiated Anti - PD - 1 Antibody Elicits Higher T Cell Activation in Ex Vivo Human Assays than a Currently Marketed Anti - PD - 1 Antibody November 3, 2015 Background ? Enumeral uses a unique single cell technology platform and approach to identify functionally differentiated antibody candidates ? Enumeral has identified two distinct classes of ant
October 2, 2015	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 28, 2015 Enumeral Biomedical Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 000-55415 99-0376434 (State or Other Jurisdiction of Incorporatio
October 2, 2015	424B3	Prospectus Supplement No. 10 (To Prospectus filed on July 6, 2015, as supplemented by Prospectus Supplement No. 1 dated July 14, 2015, Prospectus Supplement No. 2 dated July 28, 2015, Prospectus Supplement No. 3 dated August 4, 2015, Prospectus Suppl Filed Pursuant to Rule 424(b)(3) and Rule 424(c) Registration No. 333-198847 Prospectus Supplement No. 10 (To Prospectus filed on July 6, 2015, as supplemented by Prospectus Supplement No. 1 dated July 14, 2015, Prospectus Supplement No. 2 dated July 28, 2015, Prospectus Supplement No. 3 dated August 4, 2015, Prospectus Supplement No. 4 dated August 12, 2015, Prospectus Supplement No. 5 dated Sept
September 30, 2015	EX-99.1	THE POWER of HUMAN™ Fall 2015 Forward Looking S tatements OTC QB: ENUM THIS PRESENTATION CONTAINS FORWARD - LOOKING STATEMENTS THAT ARE BASED ON THE COMPANY’S CURRENT EXPECTATIONS, ASSUMPTIONS, ESTIMATES AND PROJECTIONS ABOUT THE COMPANY AND THE PHAR Exhibit 99.1 THE POWER of HUMAN? Fall 2015 Forward Looking S tatements OTC QB: ENUM THIS PRESENTATION CONTAINS FORWARD - LOOKING STATEMENTS THAT ARE BASED ON THE COMPANY?S CURRENT EXPECTATIONS, ASSUMPTIONS, ESTIMATES AND PROJECTIONS ABOUT THE COMPANY AND THE PHARMACEUTICAL INDUSTRY . THE COMPANY MAKES NO REPRESENTATIONS ABOUT THE ACCURACY OF SUCH STATEMENTS ESTIMATES OR PROJECTIONS . FORWARD - LOO
September 30, 2015	424B3	Prospectus Supplement No. 9 (To Prospectus filed on July 6, 2015, as supplemented by Prospectus Supplement No. 1 dated July 14, 2015, Prospectus Supplement No. 2 dated July 28, 2015, Prospectus Supplement No. 3 dated August 4, 2015, Prospectus Supple Filed Pursuant to Rule 424(b)(3) and Rule 424(c) Registration No. 333-198847 Prospectus Supplement No. 9 (To Prospectus filed on July 6, 2015, as supplemented by Prospectus Supplement No. 1 dated July 14, 2015, Prospectus Supplement No. 2 dated July 28, 2015, Prospectus Supplement No. 3 dated August 4, 2015, Prospectus Supplement No. 4 dated August 12, 2015, Prospectus Supplement No. 5 dated Septe
September 30, 2015	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2015 Enumeral Biomedical Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 000-55415 99-0376434 (State or Other Jurisdiction (Commission Fil
September 25, 2015	8-K	Enumeral Biomedical Holdings 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 22, 2015 Enumeral Biomedical Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 000-55415 99-0376434 (State or Other Jurisdiction (Commission Fil
September 25, 2015	424B3	Prospectus Supplement No. 8 (To Prospectus filed on July 6, 2015, as supplemented by Prospectus Supplement No. 1 dated July 14, 2015, Prospectus Supplement No. 2 dated July 28, 2015, Prospectus Supplement No. 3 dated August 4, 2015, Prospectus Supple Filed Pursuant to Rule 424(b)(3) and Rule 424(c) Registration No. 333-198847 Prospectus Supplement No. 8 (To Prospectus filed on July 6, 2015, as supplemented by Prospectus Supplement No. 1 dated July 14, 2015, Prospectus Supplement No. 2 dated July 28, 2015, Prospectus Supplement No. 3 dated August 4, 2015, Prospectus Supplement No. 4 dated August 12, 2015, Prospectus Supplement No. 5 dated Septe
September 24, 2015	424B3	Prospectus Supplement No. 7 (To Prospectus filed on July 6, 2015, as supplemented by Prospectus Supplement No. 1 dated July 14, 2015, Prospectus Supplement No. 2 dated July 28, 2015, Prospectus Supplement No. 3 dated August 4, 2015, Prospectus Supple 424B3 1 s101897424b3.htm 424B3 Filed Pursuant to Rule 424(b)(3) and Rule 424(c) Registration No. 333-198847 Prospectus Supplement No. 7 (To Prospectus filed on July 6, 2015, as supplemented by Prospectus Supplement No. 1 dated July 14, 2015, Prospectus Supplement No. 2 dated July 28, 2015, Prospectus Supplement No. 3 dated August 4, 2015, Prospectus Supplement No. 4 dated August 12, 2015, Prospect
September 24, 2015	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 24, 2015 Enumeral Biomedical Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 000-55415 99-0376434 (State or Other Jurisdiction of Incorporatio
September 24, 2015	EX-99.1	Enumeral Announces Identification of Anti-PD-1 Antibodies with Potential for Differentiated Mechanism of Action Provides Update on Additional Antibody Programs Against TIM-3 and LAG-3 Exhibit 99.1 Enumeral Announces Identification of Anti-PD-1 Antibodies with Potential for Differentiated Mechanism of Action Provides Update on Additional Antibody Programs Against TIM-3 and LAG-3 CAMBRIDGE, Mass.?September 24, 2015?Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM), a biotechnology company focused on discovering and developing novel antibody immunotherapies that help the immune sys
September 18, 2015	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 18, 2015 Enumeral Biomedical Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware Delaware 99-0376434 (State or Other Jurisdiction of Incorporation
September 18, 2015	EX-99.1	C D 1 Human Tumor-Based Identification of Immune Checkpoint Targets Thomas McQuade, Yanyan Wang, Lei Wang, Najmia Amirina, Sri Vadde, Hareesh Chamarthi, Daniel Doty, Sheila Ranganath, Cokey Nguyen, Jennifer Watkins-Yoon EnumeralBiomedical Holdings, I Exhibit 99.1 C D 1 Human Tumor-Based Identification of Immune Checkpoint Targets Thomas McQuade, Yanyan Wang, Lei Wang, Najmia Amirina, Sri Vadde, Hareesh Chamarthi, Daniel Doty, Sheila Ranganath, Cokey Nguyen, Jennifer Watkins-Yoon EnumeralBiomedical Holdings, Inc., 200 CambridgeParkDrive Suite 2000, Cambridge, MA 02140 Abstract Recentadvancesinimmunecheckpoint(IC)blockadealso highlighttheneedtod
September 18, 2015	424B3	Prospectus Supplement No. 6 (To Prospectus filed on July 6, 2015, as supplemented by Prospectus Supplement No. 1 dated July 14, 2015, Prospectus Supplement No. 2 dated July 28, 2015, Prospectus Supplement No. 3 dated August 4, 2015, Prospectus Supple Filed Pursuant to Rule 424(b)(3) and Rule 424(c) Registration No. 333-198847 Prospectus Supplement No. 6 (To Prospectus filed on July 6, 2015, as supplemented by Prospectus Supplement No. 1 dated July 14, 2015, Prospectus Supplement No. 2 dated July 28, 2015, Prospectus Supplement No. 3 dated August 4, 2015, Prospectus Supplement No. 4 dated August 12, 2015, and Prospectus Supplement No. 5 dated S
September 17, 2015	424B3	Prospectus Supplement No. 5 (To Prospectus filed on July 6, 2015, as supplemented by Prospectus Supplement No. 1 dated July 14, 2015, Prospectus Supplement No. 2 dated July 28, 2015, Prospectus Supplement No. 3 dated August 4, 2015, and Prospectus Su 424B3 1 s101839424b3.htm 424B3 Filed Pursuant to Rule 424(b)(3) and Rule 424(c) Registration No. 333-198847 Prospectus Supplement No. 5 (To Prospectus filed on July 6, 2015, as supplemented by Prospectus Supplement No. 1 dated July 14, 2015, Prospectus Supplement No. 2 dated July 28, 2015, Prospectus Supplement No. 3 dated August 4, 2015, and Prospectus Supplement No. 4 dated August 12, 2015) ENUM
September 17, 2015	EX-99.1	BiopharmAmerica 2015 September 17, 2015 Exhibit 99.1 BiopharmAmerica 2015 September 17, 2015 Forward Looking Statements OTC QB: ENUM THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT ARE BASED ON THE COMPANY?S CURRENT EXPECTATIONS, ASSUMPTIONS, ESTIMATES AND PROJECTIONS ABOUT THE COMPANY AND THE PHARMACEUTICAL INDUSTRY. THE COMPANY MAKES NO REPRESENTATIONS ABOUT THE ACCURACY OF SUCH STATEMENTS ESTIMATES OR PROJECTIONS. FORWARD-
September 17, 2015	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 17, 2015 Enumeral Biomedical Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 000-55415 99-0376434 (State or Other Jurisdiction of Incorporatio
August 12, 2015	EX-99.1	Enumeral Reports Second Quarter 2015 Financial Results Exhibit 99.1 Enumeral Reports Second Quarter 2015 Financial Results CAMBRIDGE, Mass.?August 12, 2015?Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM) (?Enumeral? or the ?Company?), a biotechnology company focused on discovering and developing novel antibody immunotherapies that help the immune system fight cancer and other diseases, today reported financial results for the quarter ended June 30, 2
August 12, 2015	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2015 Enumeral Biomedical Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 000-55415 99-0376434 (State or Other Jurisdiction (Commission File (
August 12, 2015	424B3	Prospectus Supplement No. 4 (To Prospectus filed on July 6, 2015, as supplemented by Prospectus Supplement No. 1 dated July 14, 2015, Prospectus Supplement No. 2 dated July 28, 2015, and Prospectus Supplement No. 3 dated August 4, 2015) ENUMERAL BIOM Filed Pursuant to Rule 424(b)(3) and Rule 424(c) Registration No. 333-198847 Prospectus Supplement No. 4 (To Prospectus filed on July 6, 2015, as supplemented by Prospectus Supplement No. 1 dated July 14, 2015, Prospectus Supplement No. 2 dated July 28, 2015, and Prospectus Supplement No. 3 dated August 4, 2015) ENUMERAL BIOMEDICAL HOLDINGS, INC. This Prospectus Supplement No. 4 supplements the in
August 4, 2015	424B3	Prospectus Supplement No. 3 (To Prospectus filed on July 6, 2015, as supplemented by Prospectus Supplement No. 1 dated July 14, 2015 and Prospectus Supplement No. 2 dated July 28, 2015) ENUMERAL BIOMEDICAL HOLDINGS, INC. Filed Pursuant to Rule 424(b)(3) and Rule 424(c) Registration No. 333-198847 Prospectus Supplement No. 3 (To Prospectus filed on July 6, 2015, as supplemented by Prospectus Supplement No. 1 dated July 14, 2015 and Prospectus Supplement No. 2 dated July 28, 2015) ENUMERAL BIOMEDICAL HOLDINGS, INC. This Prospectus Supplement No. 3 supplements the information contained in the Prospectus, dated as of
August 4, 2015	EX-99.1	Enumeral Appoints Robert J. Easton to its Board of Directors Exhibit 99.1 Enumeral Appoints Robert J. Easton to its Board of Directors CAMBRIDGE, Mass.?July 30, 2015?Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM), today announced that it has appointed Robert J. Easton to its Board of Directors. Mr. Easton is a recognized leader in the life sciences and healthcare industries, having led strategy development and supervised opportunity assessments for hundre
August 4, 2015	EX-24.1	POWER OF ATTORNEY Exhibit 24.1 POWER OF ATTORNEY Know all by these presents that the undersigned hereby constitutes and appoints each of Arthur H. Tinkelenberg and Kevin G. Sarney, or either of them signing individually, and with full power of substitution, the undersigned's true and lawful attorney-in-fact to: (1) prepare, execute in the undersigned?s name and on the undersigned?s behalf, and submit to the U.S. Se
August 4, 2015	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events 8-K 1 s1015908k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2015 Enumeral Biomedical Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 000-55415 99-0376434 (State or Other Jurisdict
July 28, 2015	424B3	Prospectus Supplement No. 2 (To Prospectus filed on July 6, 2015, as supplemented by Prospectus Supplement No. 1 dated July 14, 2015) ENUMERAL BIOMEDICAL HOLDINGS, INC. Filed Pursuant to Rule 424(b)(3) and Rule 424(c) Registration No. 333-198847 Prospectus Supplement No. 2 (To Prospectus filed on July 6, 2015, as supplemented by Prospectus Supplement No. 1 dated July 14, 2015) ENUMERAL BIOMEDICAL HOLDINGS, INC. This Prospectus Supplement No. 2 supplements the information contained in the Prospectus, dated as of July 6, 2015, as amended by Prospectus Supplement No
July 28, 2015	8-K	Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 s1015398k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2015 Enumeral Biomedical Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 000-55415 99-0376434 (State or Other Jurisdict
July 28, 2015	EX-99.1	Enumeral Drug Discovery & Development July 2015 Program Updates Exhibit 99.1 Enumeral Drug Discovery & Development July 2015 Program Updates 2 Overview ? Program Overview ? PD - 1 ? TIM - 3 ? TCR recovery (single cell) 2 Program Overview 4 Improving anti - tumor effects of IMR - targeted antibodies 4 Tumor cells Stromal cells Homing Suppression Tolerance Tumor reactive T cells traffic to the tumor Inhibitory signals inhibit effector function Immune system may
July 14, 2015	EX-99.2	July 14, 2015 EX-99.2 3 s101462ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 July 14, 2015 Dear Fellow Shareholders: As we mark the midpoint of 2015, we wanted to provide you with an update on the company’s recent progress and share some exciting developments in our research and development programs that we reported earlier this week. As you know, the Enumeral team is focused on applying our proprietary platform technol
July 14, 2015	EX-99.1	Enumeral Announces Progress in PD-1, TIM-3 and Other Pipeline Programs Exhibit 99.1 Enumeral Announces Progress in PD-1, TIM-3 and Other Pipeline Programs CAMBRIDGE, Mass.?July 14, 2015?Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM), today announced recent progress in its PD-1 antibody program. Enumeral also provided an update on the progress of additional programs in the Company?s R&D pipeline, including its TIM-3 antibody program. Enumeral has identified antibodi
July 14, 2015	424B3	Prospectus Supplement No. 1 (To Prospectus filed on July 6, 2015) ENUMERAL BIOMEDICAL HOLDINGS, INC. Filed Pursuant to Rule 424(b)(3) and Rule 424(c) Registration No. 333-198847 Prospectus Supplement No. 1 (To Prospectus filed on July 6, 2015) ENUMERAL BIOMEDICAL HOLDINGS, INC. This Prospectus Supplement No. 1 supplements the information contained in the Prospectus, dated as of July 6, 2015, relating to the resale of up to 52,154,760 shares of our common stock by selling stockholders. This Prospe
July 14, 2015	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 14, 2015 Enumeral Biomedical Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 000-55415 99-0376434 (State or Other Jurisdiction (Commission File (I.
July 6, 2015	424B3	ENUMERAL BIOMEDICAL HOLDINGS, INC. 52,154,760 Shares Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-198847 ENUMERAL BIOMEDICAL HOLDINGS, INC. Prospectus 52,154,760 Shares Common Stock This prospectus relates to the resale of up to 52,154,760 shares of common stock, par value $0.001 per share (?Common Stock?), of Enumeral Biomedical Holdings, Inc. (?we? or the ?Company?) held by certain selling stockholders, consisting of the following: ? 42,8
June 30, 2015	CORRESP	Enumeral Biomedical Holdings ESP June 30, 2015 VIA EDGAR Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Re: Enumeral Biomedical Holdings, Inc. Post-Effective Amendment No. 1 to Registration Statement on Form S-1 Filed May 28, 2015 File No. 333-198847 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, Enumeral Biomedical Holdings, Inc., a Delaware corporation (?Enumeral?), here
June 19, 2015	8-K	Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2015 Enumeral Biomedical Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 000-55415 99-0376434 (State or Other Jurisdiction (Commission File (I.
June 19, 2015	424B3	Prospectus Supplement No. 14 (To Prospectus filed on November 10, 2014, as supplemented by Prospectus Supplement No. 1 dated November 12, 2014, Prospectus Supplement No. 2 dated November 14, 2014, Prospectus Supplement No. 3 dated December 18, 2014, Filed Pursuant to Rule 424(b)(3) and Rule 424(c) Registration No. 333-198847 Prospectus Supplement No. 14 (To Prospectus filed on November 10, 2014, as supplemented by Prospectus Supplement No. 1 dated November 12, 2014, Prospectus Supplement No. 2 dated November 14, 2014, Prospectus Supplement No. 3 dated December 18, 2014, Prospectus Supplement No. 4 dated January 9, 2015, Prospectus Supplement
June 19, 2015	EX-10.1	LEASE TERMINATION AGREEMENT Exhibit 10.1 LEASE TERMINATION AGREEMENT This Lease Termination Agreement (this ?Agreement?) is made as of the 17th day of June, 2015 by and between DWF IV ONE KENDALL, LLC, a Delaware limited liability company, as landlord (?Landlord?), and ENUMERAL BIOMEDICAL CORP., a Delaware corporation, as tenant (?Tenant?). BACKGROUND A. Landlord and Tenant are holders of the landlord?s and tenant?s interest
May 28, 2015	POS AM	Enumeral Biomedical Holdings POS AM As filed with the Securities and Exchange Commission on May 28, 2015 Registration No.
May 22, 2015	424B3	Prospectus Supplement No. 13 (To Prospectus filed on November 10, 2014, as supplemented by Prospectus Supplement No. 1 dated November 12, 2014, Prospectus Supplement No. 2 dated November 14, 2014, Prospectus Supplement No. 3 dated December 18, 2014, 424B3 1 s101201424b3.htm 424B3 Filed Pursuant to Rule 424(b)(3) and Rule 424(c) Registration No. 333-198847 Prospectus Supplement No. 13 (To Prospectus filed on November 10, 2014, as supplemented by Prospectus Supplement No. 1 dated November 12, 2014, Prospectus Supplement No. 2 dated November 14, 2014, Prospectus Supplement No. 3 dated December 18, 2014, Prospectus Supplement No. 4 dated January
May 22, 2015	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2015 Enumeral Biomedical Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 000-55415 99-0376434 (State or Other Jurisdiction (Commission File (I.R
May 22, 2015	EX-10.1	ENUMERAL BIOMEDICAL HOLDINGS, INC. AMENDMENT NO. 2 TO 2014 EQUITY INCENTIVE PLAN EX-10.1 2 s101191ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 ENUMERAL BIOMEDICAL HOLDINGS, INC. AMENDMENT NO. 2 TO 2014 EQUITY INCENTIVE PLAN Pursuant to Article XV of the 2014 Equity Incentive Plan, as amended (the “Plan”), of Enumeral Biomedical Holdings, Inc., a Delaware corporation (the “Company”), the Plan be, and hereby is, amended as set forth below. Capitalized terms used and not defined herein s
May 20, 2015	DEF 14A	Enumeral Biomedical Holdings DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ??) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Def
May 20, 2015	DEFA14A	Enumeral Biomedical Holdings DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin
May 20, 2015	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2015 Enumeral Biomedical Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 000-55415 99-0376434 (State or Other Jurisdiction (Commission File (I.R
May 20, 2015	424B3	Prospectus Supplement No. 12 (To Prospectus filed on November 10, 2014, as supplemented by Prospectus Supplement No. 1 dated November 12, 2014, Prospectus Supplement No. 2 dated November 14, 2014, Prospectus Supplement No. 3 dated December 18, 2014, Filed Pursuant to Rule 424(b)(3) and Rule 424(c) Registration No. 333-198847 Prospectus Supplement No. 12 (To Prospectus filed on November 10, 2014, as supplemented by Prospectus Supplement No. 1 dated November 12, 2014, Prospectus Supplement No. 2 dated November 14, 2014, Prospectus Supplement No. 3 dated December 18, 2014, Prospectus Supplement No. 4 dated January 9, 2015, Prospectus Supplement
May 19, 2015	PRER14A	Enumeral Biomedical Holdings PRER14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 2) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: x Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defi
May 19, 2015	CORRESP	Enumeral Biomedical Holdings ESP May 19, 2015 VIA EDGAR AND FEDEX Jeffrey P. Riedler Assistant Director Division of Corporation Finance Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Re: Enumeral Biomedical Holdings, Inc. Revised Preliminary Proxy Statement on Schedule 14A Filed May 15, 2015 File No. 000-55415 Dear Mr. Riedler: On behalf of Enumeral Biomedical Holdings, Inc. (the ?Company?), I am sendi
May 18, 2015	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2015 Enumeral Biomedical Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 000-55415 99-0376434 (State or Other Jurisdiction (Commission File (I.R
May 18, 2015	424B3	Prospectus Supplement No. 11 (To Prospectus filed on November 10, 2014, as supplemented by Prospectus Supplement No. 1 dated November 12, 2014, Prospectus Supplement No. 2 dated November 14, 2014, Prospectus Supplement No. 3 dated December 18, 2014, Filed Pursuant to Rule 424(b)(3) and Rule 424(c) Registration No. 333-198847 Prospectus Supplement No. 11 (To Prospectus filed on November 10, 2014, as supplemented by Prospectus Supplement No. 1 dated November 12, 2014, Prospectus Supplement No. 2 dated November 14, 2014, Prospectus Supplement No. 3 dated December 18, 2014, Prospectus Supplement No. 4 dated January 9, 2015, Prospectus Supplement
May 18, 2015	EX-99.1	THE POWER ofHUMAN™ May 2015 Exhibit 99.1 THE POWER ofHUMAN? May 2015 Forward Looking Statements OTC QB: ENUM THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT ARE BASED ON THE COMPANY?S CURRENT EXPECTATIONS, ASSUMPTIONS, ESTIMATES AND PROJECTIONS ABOUT THE COMPANY AND THE PHARMACEUTICAL INDUSTRY. THE COMPANY MAKES NO REPRESENTATIONS ABOUT THE ACCURACY OF SUCH STATEMENTS ESTIMATES OR PROJECTIONS. FORWARD-LOOKING STAT
May 15, 2015	EX-99.1	Enumeral Reports First Quarter 2015 Financial Results Exhibit 99.1 Enumeral Reports First Quarter 2015 Financial Results CAMBRIDGE, Mass.-May 15, 2015-Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM) (?Enumeral? or the ?Company?), a biotechnology company focused on discovering and developing novel antibody immunotherapies that help the immune system fight cancer and other diseases, today reported financial results for the quarter ended March 31, 2015
May 15, 2015	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 s1011158k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2015 Enumeral Biomedical Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 000-55415 99-0376434 (State or Other Jurisdicti
May 15, 2015	PRER14A	Enumeral Biomedical Holdings PRER14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: x Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defi
May 15, 2015	CORRESP	Enumeral Biomedical Holdings ESP May 15, 2015 VIA EDGAR AND OVERNIGHT DELIVERY Jeffrey P. Riedler Assistant Director Division of Corporation Finance Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Re: Enumeral Biomedical Holdings, Inc. Preliminary Proxy Statement on Schedule 14A Filed May 8, 2015 File No. 000-55415 Dear Mr. Riedler: On behalf of Enumeral Biomedical Holdings, Inc. (the ?Company?), I am s
May 15, 2015	424B3	Prospectus Supplement No. 10 (To Prospectus filed on November 10, 2014, as supplemented by Prospectus Supplement No. 1 dated November 12, 2014, Prospectus Supplement No. 2 dated November 14, 2014, Prospectus Supplement No. 3 dated December 18, 2014, 424B3 1 s101121424b3.htm 424B3 Filed Pursuant to Rule 424(b)(3) and Rule 424(c) Registration No. 333-198847 Prospectus Supplement No. 10 (To Prospectus filed on November 10, 2014, as supplemented by Prospectus Supplement No. 1 dated November 12, 2014, Prospectus Supplement No. 2 dated November 14, 2014, Prospectus Supplement No. 3 dated December 18, 2014, Prospectus Supplement No. 4 dated January
May 8, 2015	PRE 14A	Enumeral Biomedical Holdings PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: x Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin
April 28, 2015	424B3	Prospectus Supplement No. 9 (To Prospectus filed on November 10, 2014, as supplemented by Prospectus Supplement No. 1 dated November 12, 2014, Prospectus Supplement No. 2 dated November 14, 2014, Prospectus Supplement No. 3 dated December 18, 2014, P Filed Pursuant to Rule 424(b)(3) and Rule 424(c) Registration No. 333-198847 Prospectus Supplement No. 9 (To Prospectus filed on November 10, 2014, as supplemented by Prospectus Supplement No. 1 dated November 12, 2014, Prospectus Supplement No. 2 dated November 14, 2014, Prospectus Supplement No. 3 dated December 18, 2014, Prospectus Supplement No. 4 dated January 9, 2015, Prospectus Supplement N
April 28, 2015	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2015 Enumeral Biomedical Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 333-185891 99-0376434 (State or Other Jurisdiction (Commission File (
April 28, 2015	EX-99.1	THE POWER of HUMAN™ April 2015 Exhibit 99.1 THE POWER of HUMAN? April 2015 Forward Looking S tatements OTC QB: ENUM THIS PRESENTATION CONTAINS FORWARD - LOOKING STATEMENTS THAT ARE BASED ON THE COMPANY?S CURRENT EXPECTATIONS, ASSUMPTIONS, ESTIMATES AND PROJECTIONS ABOUT THE COMPANY AND THE PHARMACEUTICAL INDUSTRY. THE COMPANY MAKES NO REPRESENTATIONS ABOUT THE ACCURACY OF SUCH STATEMENTS ESTIMATES OR PROJECTIONS. FORWARD - LOOK
April 17, 2015	424B3	Prospectus Supplement No. 8 (To Prospectus filed on November 10, 2014, as supplemented by Prospectus Supplement No. 1 dated November 12, 2014, Prospectus Supplement No. 2 dated November 14, 2014, Prospectus Supplement No. 3 dated December 18, 2014, P Filed Pursuant to Rule 424(b)(3) and Rule 424(c) Registration No. 333-198847 Prospectus Supplement No. 8 (To Prospectus filed on November 10, 2014, as supplemented by Prospectus Supplement No. 1 dated November 12, 2014, Prospectus Supplement No. 2 dated November 14, 2014, Prospectus Supplement No. 3 dated December 18, 2014, Prospectus Supplement No. 4 dated January 9, 2015, Prospectus Supplement N
April 17, 2015	8-K	Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2015 Enumeral Biomedical Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 333-185891 99-0376434 (State or Other Jurisdiction of Incorporation)
April 10, 2015	S-8	Enumeral Biomedical Holdings S-8 As filed with the Securities and Exchange Commission on April 10, 2015 Registration No.
April 7, 2015	EX-99.1	Enumeral Biomedical Antibody Immunotherapy Programs April 2015 Exhibit 99.1 Enumeral Biomedical Antibody Immunotherapy Programs April 2015 Enumeral Overview Enumeral?s mission is to discover and develop best - in - class antibody immunotherapies using our proprietary platform that uniquely leverages human cell biology ? The field agrees that combination therapies will be necessary to drive higher response rates? ? ? And that there is currently little to no da
April 7, 2015	424B3	Prospectus Supplement No. 7 (To Prospectus filed on November 10, 2014, as supplemented by Prospectus Supplement No. 1 dated November 12, 2014, Prospectus Supplement No. 2 dated November 14, 2014, Prospectus Supplement No. 3 dated December 18, 2014, P Filed Pursuant to Rule 424(b)(3) and Rule 424(c) Registration No. 333-198847 Prospectus Supplement No. 7 (To Prospectus filed on November 10, 2014, as supplemented by Prospectus Supplement No. 1 dated November 12, 2014, Prospectus Supplement No. 2 dated November 14, 2014, Prospectus Supplement No. 3 dated December 18, 2014, Prospectus Supplement No. 4 dated January 9, 2015, Prospectus Supplement N
April 7, 2015	8-K	Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 s1009558k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 7, 2015 Enumeral Biomedical Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 333-185891 99-0376434 (State or Other Jurisdic
April 3, 2015	EX-24.1	POWER OF ATTORNEY Exhibit 24.1 POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints each of Arthur Tinkelenberg and Kevin Sarney, or either of them signing individually, and with full power of substitution, the undersigned's true and lawful attorney-in-fact to: (1) prepare, execute in the undersigned?s name and on the undersigned?s behalf, and submit to the U.S. Securit
April 3, 2015	EX-24.1	POWER OF ATTORNEY EX-24.1 2 ex24-1.htm EX-24.1 Exhibit 24.1 POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints each of Arthur Tinkelenberg and Kevin Sarney, or either of them signing individually, and with full power of substitution, the undersigned's true and lawful attorney-in-fact to: (1) prepare, execute in the undersigned’s name and on the undersigned’s behalf, a
April 3, 2015	EX-24.1	POWER OF ATTORNEY Exhibit 24.1 POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints each of Arthur Tinkelenberg and Kevin Sarney, or either of them signing individually, and with full power of substitution, the undersigned's true and lawful attorney-in-fact to: (1) prepare, execute in the undersigned?s name and on the undersigned?s behalf, and submit to the U.S. Securit
April 3, 2015	EX-24.1	POWER OF ATTORNEY Exhibit 24.1 POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints Kevin Sarney, with full power of substitution, the undersigned's true and lawful attorney-in-fact to: (1) prepare, execute in the undersigned?s name and on the undersigned?s behalf, and submit to the U.S. Securities and Exchange Commission (the ?SEC?) a Form ID, including amendments ther
April 3, 2015	EX-24.1	POWER OF ATTORNEY Exhibit 24.1 POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints each of Arthur Tinkelenberg and Kevin Sarney, or either of them signing individually, and with full power of substitution, the undersigned's true and lawful attorney-in-fact to: (1) prepare, execute in the undersigned’s name and on the undersigned’s behalf, and submit to the U.S. Securit

ENUM / Enumeral Biomedical Holdings, Inc. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

Mga Batayang Estadistika

SEC Filings

SEC Filings (Chronological Order)